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Abstract 
 HIV infection remains a worldwide epidemic without prospects of a cure. While 
antiretroviral therapy (ART) successfully decreases plasma viral load and prevents new 
cells from becoming infected, long-lived latently infected cells remain in blood and 
tissues. CD4+ T cells have been extensively studied and characterized as a major latent 
reservoir; however less is known about macrophages, another cell infected by HIV. A 
better understanding of all the latent reservoirs is needed in order to devise strategies for 
eradication.  
HIV infects both CD4+ T cells and cells from the myeloid lineage such as blood 
monocytes and tissue macrophages early during infection. While most CD4+ T cells 
become activated and die during the infection, some become memory cells and are able 
to persist in the body from months to years. Recent findings suggest that macrophages 
behave in a similar manner and have been shown to proliferate in situ contributing to new 
cells. Furthermore, tissue macrophages are found throughout the body in organs such as 
lungs, spleen, and brain among others. Infection of macrophages in these tissues has not 
been characterized nor the frequency of these cells compared to infected resting CD4+ T 
cells. Therefore we developed methods, which quantitated and compared both major 
cellular reservoirs (CD4+ T cells and macrophages). CD4+ T cells from the blood and 
spleen were assayed using the quantitative viral outgrowth assay (QVOA) while 
monocytes in the blood and macrophages in the bronchoalveolar lavage fluid, lungs, 
spleen and brain of SIV-infected pigtailed macaques were assayed using a similar assay, 
the macrophage quantitative viral outgrowth assay (MΦ-QVOA).  
 iii 
The era of ART led to a decline in the frequency of HIV associated pathologies 
such as HIV-associated neurocognitive disorders (HAND). However, mild to moderate 
forms of HAND are still observed in viral controlled patients on successful ART. 
Markers of inflammation in the CSF are often reported in ART-treated patients showing 
signs of neurological impairment; therefore, low levels of macrophage activation and 
viral production in the brain are presumed to contribute to HAND. A debate still exists as 
to whether macrophages fit the definition of a latent reservoir. Replication-competent 
virus has not been recovered from latently infected macrophages in SIV or HIV-infected 
individuals on long-term suppression. Therefore, we used our MΦ-QVOA assay to 
quantitate the frequency of infection of macrophages in brain of SIV-infected ART-
treated macaques. Despite long-term ART treatment of SIV-infected macaques, brain 
macrophages were shown to contain replication competent virus demonstrating for the 
first time latently infected microglia. In addition, markers of macrophage activation and 
neuronal damage were detected in the CSF of the ART suppressed macaques, suggesting 
in part that latently infected macrophages contribute to CNS inflammation. In situ 
hybridization from two brain regions confirmed the presence of rare SIV RNA positive 
cells but underestimated the size of the reservoir, as did tissue RNA and DNA 
measurements. The virus obtained in the MΦ-QVOA cultures caused productive 
infection in peripheral blood mononuclear cells de novo, thus demonstrating that the 
macrophage reservoir contained functional viral genomes and could spread from the 
brain to the periphery upon ART interruption. Finally, monocytes in the blood and 
macrophages in the bronchoalveolar lavage fluid, lungs, and spleen were assayed using 
the MΦ-QVOA and compared to the frequency of latently infected resting CD4+ T cells 
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in the blood and spleen of SIV-infected ART-treated pigtailed macaques. Our findings 
confirmed that macrophages are latently infected in these peripheral tissues and the size 
of the reservoir was equivalent to the resting CD4+ T cell reservoir.  
The data presented here demonstrated that macrophages are yet another obstacle 
to HIV eradication, and suggest that macrophages contribute to the ongoing viral 
replication in tissues, thus playing a pivotal role in long-term tissue inflammation. 
 
Thesis Advisor: Janice Clements, Ph.D. 
Thesis Reader: Alan Scott, Ph.D. 
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 I. Introduction 
 
 2 
History of HIV Infection 
The first cases of an acquired immune deficiency disorder were described in 1981 
when previously healthy individuals started showing signs of Pneumocystis carinii (now 
known to be P. jiroveci) pneumonia and Kaposi sarcoma, which were accompanied by 
depletion of CD4+ lymphocytes (1-4). Soon thereafter, a virus was isolated and linked to 
be the disease called the acquired immune deficiency disorder or AIDS (5). However, it 
wasn’t until 1985 that the term Human Immunodeficiency Virus (HIV) was used (6). 
Genetic evaluation of the virus estimates that humans became infected with strains of 
HIV in 1920 (7), during a crossover event of Simian Immunodeficiency Virus (SIV) most 
likely caused by hunting of non-human primates in Africa (8, 9). Early findings showed 
that HIV is a member of the lentivirus family and therefore infects both macrophages and 
CD4+ T cells (10-12) and shares the characteristic long incubation of the virus prior to 
clinical manifestations and terminal disease (13).  
Approximately 37 million individuals are currently living with HIV worldwide 
according to the World Health Organization (WHO) statistics from 2014. HIV continues 
to be a major public health issue with more than 70% of HIV infections located in sub-
Saharan Africa. Since first being described as a new disease, HIV has taken the lives of 
34 million people, and the WHO estimates that 2 million people become infected every 
year. Antiretroviral therapies (ART) have been successful in controlling viremia in HIV-
infected patients and help prevent the progression to AIDS; however, there is no vaccine 
that prevents infection or a cure for the infected individuals so ART must be taken life-
long (14). Further research is needed to advance the understanding of HIV persistence 
despite ART and to better identify viable strategies for an HIV cure (15). 
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Current Strategies for Eradication 
HIV persistence despite ART is thought to be the product of long-lived latently 
infected cells, de novo infection, and failure of the immune system to detect and eliminate 
the latent reservoir. The best-characterized latent reservoir is resting CD4+ T cells in 
HIV-infected patient on successful ART regimens (16, 17). Macrophages do not 
currently fit the definition of a latent reservoir (18); therefore current strategies towards 
HIV eradication have been developed to target only CD4+ T cells.  
The challenge to complete clearance of HIV is the ability of the virus to integrate 
its viral DNA into the genome of infected cells. ART prevents new infection of 
susceptible cells but treatment neither eliminates infected cells nor removes the viral 
genome from the cellular genome. Unless all infected cells that harbor replication 
competent virus are cleared, infection restarts when ART is interrupted. The only case of 
an HIV cure to date is a single HIV-infected man who received a bone marrow transplant 
from a donor who had a homozygous CCR5 delta32 deletion (19, 20). Without a 
functional CCR5 chemokine receptor, HIV does not efficiently infect human cells. After 
discontinuation of ART and full reconstitution of blood and tissues with donor-derived 
cells, the patient showed no sign of HIV infection. This case renewed interest in devising 
an HIV cure by activating latently infected cells such that the immune system would 
recognize the infected cells and eliminate the reservoir, a strategy termed “Shock-and-
kill” (21, 22).  
Several methods have been tried to activate and eliminate latently infected resting 
CD4+ T cell (23, 24). These include activating T cells with cytokines (25), histone 
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deacetylase inhibitors (26), phorbol esters that stimulate protein kinase C activity (27, 28) 
and RNA guided excision of integrated HIV (29). While some of these methods proved 
promising in decreasing the number of latently infected resting CD4+ T cells in in vitro 
assays, none resulted in a decrease on the CD4+ T cell reservoir in human clinical trials 
(22, 30, 31). Further, none of the approaches used to target the CD4+ T cell reservoir are 
known to target other potential cellular reservoirs (macrophages). 
 
Macrophage Heterogeneity 
Macrophages are the first line of defense against pathogens and become 
differentially activated in response to the tissue environment in which they reside. 
Macrophages have been characterized in vitro as classically activated (M1), or 
alternatively activated (M2a, M2b and M2c) (32, 33). Classical activation of 
macrophages was initially attributed to a Th1 type of response to the secreted molecules 
of CD4+ Th1 cells. M1 macrophages, which are induced by IFNγ, TNFα, and LPS, 
display a pro-inflammatory phenotype, enhanced microbicidal activity and secretion of 
pro-inflammatory cytokines (34). Following the same rationale, alternatively activated 
macrophages were attributed to a Th2 type of response and were eventually expanded to 
include all other types of macrophages. M2a macrophages, which are induced by IL4 and 
IL13, play an important role in wound healing, allergy, response to parasites, and tissue 
remodeling (35). M2b macrophages are induced by immune complexes and the activation 
of Fcγ receptors in the presence of TLR signals such as LPS or IL1β through the TLR4 
receptor and IL1R respectively (36). Finally, M2c macrophages, which are induced by 
IL10, TGFβ, and glucocorticoids, have also been termed de-activated or regulatory 
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macrophages due to their production of anti-inflammatory cytokines (34, 36). 
Macrophages phenotypes have been studied mainly in vitro and not in tissues in situ. The 
role of macrophage polarization in viral infection has begun to be studied in vitro but the 
role of macrophage polarization in vivo and is role in viral infections and in the case of 
HIV viral latency in largely unknown.  
 
Macrophages in HIV infection  
Antiretroviral drugs are able to diminish viral load below the limit of detection, 
but latent reservoirs persist in resting CD4+ T cells and macrophages in tissues (37). 
Unlike infected CD4+ T cells, tissue macrophages do not undergo cell death as a result of 
infection and can harbor latent viral DNA for long periods of time (38, 39). Moreover, 
HIV/SIV infected macrophages are not efficiently killed by CD8+ T cells like infected 
CD4+ T cells (40, 41). Finally, ART often displays differential antiviral activity in 
macrophages compared to CD4+ T cells (38). While the CD4+ latent reservoirs in HIV 
and SIV have been well-characterized, little is known about the establishment and extent 
of latent reservoirs in tissue macrophage populations and in particular, in the highly 
diverse populations of tissue-resident macrophages.  
Recent fate mapping analyses show that tissue-resident macrophages, such as 
alveolar macrophages, splenic red pulp macrophages, and microglia, are derived from 
embryonic yolk sac progenitor cells that self-renew with little to no contribution from 
circulating monocytes during homeostasis contrary to previous beliefs (42-47). Our lab 
also recently demonstrated that the spleen is comprised of a mixture of three populations 
of macrophages, based on the expression of CD68, CD163 and Mac387 markers, which 
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become differentially infected in pigtailed macaques. In this study, fetal derived 
CD163+CD68+ macrophages became preferentially depleted with SIV infection and the 
changes in these cell types remained throughout the course of infection (48). Moreover, 
macrophage CD163 expression was upregulated, which has been previously shown to 
promote higher HIV infection in these cells (49). Thus, HIV/ SIV infection not only 
affects the polarization of tissue macrophages but also changes the macrophage 
populations that comprise the tissue. It is unclear whether macrophage ontogeny drives 
differential latent states or how the different macrophage populations respond to 
polarization agents or activating stimuli. Further research is needed in the area of 
macrophage infection and subsequent latency, despite the lack of specific mechanisms of 
HIV/SIV infection and latency it is clear that macrophages differ substantially from CD4+ 
T cells.  
 
Quantitative viral outgrowth assay (QVOA) 
Our laboratory developed and characterized a consistent, accelerated SIV 
macaque model for HIV AIDS and neurologic disease (21). In this model, infection of 
macrophages occurs in lymph nodes, spleen, heart, lungs, peripheral nervous systems, 
and brain (50-54). Non-human primate models provide a tool to study systemic SIV 
infection and offer a window into SIV infection of tissue macrophages compared to CD4+ 
T cells. The frequency of HIV or SIV infection of macrophages in tissues has been 
previously examined (55, 56). However, in most of these studies infection was measured 
by viral DNA in cells isolated from tissues; this approach overestimates the frequency of 
productively infected cells due to the large presence of defective proviruses in infected 
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cells in vivo (57, 58). A more rigorous approach to quantify cells that harbor replication 
competent virus is the quantitative viral outgrowth assay (QVOA). The QVOA was 
developed to quantitate the number of HIV-infected resting CD4+ T cells that produce 
infectious virus (59-61). This assay has been used to quantify the number of resting CD4+ 
lymphocytes in vivo in HIV infected individuals on antiretroviral therapy (ART) that 
harbor replication-competent viral genomes and serves as the gold standard for studying 
viral latency in lymphocytes (57, 59).  
Using the same concept, we developed a macrophage quantitative viral outgrowth 
assay (MΦ-QVOA) to measure the size of the macrophage cellular reservoir in 
comparison to the resting CD4+ T cell reservoir. This work provides the first evidence 
that macrophages contain replication-competent virus that leads to latent infection in 
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ABSTRACT 
Despite the success of combined antiretroviral therapy (ART), HIV remains a life-
long infection because of latent viral reservoirs in infected patients. The contribution of 
CD4+ T cells to infection and disease progression has been extensively studied. However, 
during early HIV infection macrophages in the brain and other tissues are infected and 
contribute to tissue specific diseases, such as encephalitis and dementia in brain and 
pneumonia in lung. The extent of infection of monocytes and macrophages has not been 
rigorously assessed with assays comparable to those used to study infection of CD4+ T 
cells and to evaluate the number of CD4+ T cells that harbor infectious viral genomes. To 
assess the contribution of productively infected monocytes and macrophages to HIV and 
SIV infected cells in vivo, we developed a quantitative virus outgrowth assay (QVOA) 
based on similar assays used to quantitate CD4+ T cell latent reservoirs in ART 
suppressed HIV- and SIV-infected individuals. CD11b+ selected myeloid cells were 
serially diluted and co-cultured with susceptible cells to amplify virus. TCRβ RNA was 
measured as a control to assess the potential contribution of CD4+ T cells in the assay. 
Virus production in the supernatant was quantitated by qRT-PCR. Productively infected 
myeloid cells were detected in blood, bronchoalveolar lavage, lungs, spleen, and brain, 
demonstrating that these cells persist throughout SIV infection and have the potential to 
contribute to the viral reservoir during ART.
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IMPORTANCE 
Infection of CD4+ T cells and their role as latent reservoirs has been rigorously 
assessed; however, the frequency of productively infected monocytes and macrophages 
in vivo has not been similarly studied. Myeloid cells, unlike lymphocytes, are resistant to 
the cytopathic effects of HIV. Moreover, tissue-resident macrophages have the ability to 
self-renew and persist in the body for months to years. Thus, tissue macrophages, once 
infected, have the characteristics of a potentially stable viral reservoir. A better 
understanding of the number of productively infected macrophages is crucial to further 
evaluate the role of infected myeloid cells as a potential viral reservoir. Here we compare 
the frequency of productively infected CD4+ T cells and macrophages in a SIV-macaque 
model. We developed a critical assay that will allow us to quantitate myeloid cells 
containing viral genomes that lead to productive infection in SIV-infected macaques and 
assess the role of macrophages as potential reservoirs. 
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INTRODUCTION 
Lentiviruses infect myeloid lineage cells in tissues and these cells are responsible 
for the multi-organ disease characteristic of this family of retroviruses (1-3). HIV was the 
first primate lentivirus identified that infects CD4+ T cells as well as myeloid cells in 
blood and tissues of infected individuals (4-6). HIV infects myeloid cells in lymph nodes, 
spleen, heart, lungs, peripheral nervous system, and the central nervous system (CNS) (7-
11). HIV encodes genes that specifically interact and/or interfere with restriction factors 
present in myeloid cells, providing evolutionary evidence that HIV replication in myeloid 
cells is important for virus replication and pathogenesis in vivo (12).  
Myeloid cells were thought to be terminally differentiated cells with a limited 
lifespan. However, recent studies have demonstrated that resident tissue macrophages are 
capable of self-renewal and that monocytes from blood differentiate into distinct 
macrophage phenotypes after entering tissues (13, 14). Moreover, tissue-resident 
macrophages, such as alveolar macrophages, splenic red pulp macrophages, and 
microglia, are derived from embryonic yolk sac progenitor cells that self-renew with little 
to no contribution from circulating monocytes during homeostasis (15-18). Furthermore, 
HIV- and SIV-infected macrophages are not efficiently killed by CD8+ T cells as are 
infected CD4+ T cells (19, 20). Thus, resident tissue macrophages remain in tissues long-
term, are relatively resistant to the cytopathic effects of HIV infection compared to CD4+ 
T cells, and may serve as stable viral reservoirs. 
SIV macaque models have been used to study the pathogenesis of SIV in vivo, as 
models of HIV infection in humans. Like HIV, SIV infects both CD4+ T cells and 
macrophages in blood, tissues, and brain (21-25). Our laboratory developed and 
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characterized a consistent, accelerated SIV macaque model resulting in AIDS and CNS 
disease (in ~80% of macaques) in three months compared to the longer course of disease 
pathogenesis and frequency of CNS disease in other SIV models (21). Another model to 
study CNS infection used depletion of CD8+ T cells in SIV-infected macaques resulting 
in increased accumulation of infected macrophages in the CNS and heightened severity 
of neurological disease, suggesting that infection of macrophages plays a key role in CNS 
disease (26).  
The frequency of HIV or SIV infection of macrophages in tissues has been 
examined previously in a number of studies (27, 28). Infection is quantified by measuring 
viral DNA in cells isolated from tissues; however, this approach overestimates the 
number of productively infected CD4+ T cells due to the presence of a large proportion of 
defective proviruses in vivo (29, 30). A more rigorous approach to quantify cells that 
harbor replication competent virus is the quantitative viral outgrowth assay (QVOA), 
which quantitates the number of HIV-infected resting CD4+ T cells that produce 
infectious virus (31-33). This assay has been used to quantify the number of resting CD4+ 
lymphocytes in vivo in HIV infected individuals on antiretroviral therapy (ART) that 
harbor replication competent viral genomes and serves as one of the major assays for 
studying viral latency in that cell type (29, 31).  
Using a QVOA that our laboratory developed for SIV-infected non-human 
primate CD4+ T cells, we previously demonstrated that the number of infected resting 
CD4+ T cells in SIV-suppressed macaque blood and tissues was equivalent to the number 
of infected resting CD4+ T cells in HIV-infected humans on ART (31-35). In this study, 
we developed a novel macrophage quantitative viral outgrowth assay (MΦ-QVOA) to 
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assess the frequency of productively SIV-infected monocytes (in blood) and macrophages 
(in tissues) using a well-characterized SIV macaque model (36-38). To determine the 
potential contribution of CD4+ T cells to the quantitation of macrophages, we also 
assessed the number of CD3+ T cells in each assay by measuring TCRβ RNA.  
Using the myeloid MΦ-QVOA, we show that during chronic SIV infection 
productively infected monocytes or macrophages are present in blood, bronchoalveolar 
lavage (BAL), lungs, spleen, and brain. This assay can also be used to quantify HIV and 
SIV productively infected myeloid cells that may contribute to viral persistence and 
latency in ART-treated humans and macaques.
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MATERIALS AND METHODS 
Animal Studies 
Fourteen juvenile pigtailed macaques (Macaca nemestrina) were inoculated 
intravenously with the SIV/DeltaB670 swarm and the macrophage-tropic clone SIV/17E-
Fr as previously described (36, 38, 39). One macaque Pm11 was treated 12 days post-
inoculation (d.p.i.) with 12.5 mg fluconazole and 5mg paroxetine once/day orally and 
euthanized at ~80 d.p.i. as previously described (40). Three macaques Pm12, Pm13, and 
Pm14 were treated 28 days prior to virus inoculation with 2mg/kg minocycline twice/day 
orally and were euthanized during asymptomatic infection (~35 d.p.i.). These macaques 
were added to the study to investigate macrophage infection at different time after 
infections. These treatments did not affect either plasma viral load or disease progression 
(40). Eleven macaques were euthanized during late-stage infection (50-87 days post-
inoculation (d.p.i.)), and three macaques were euthanized during chronic infection (34-36 
d.p.i.; Error! Reference source not found.). Blood and cerebrospinal fluid (CSF) 
samples were collected longitudinally post-infection. When macaques were euthanized, 
they were perfused with sterile saline to remove blood and circulating virus as described 
elsewhere (35). Viral loads in plasma and CSF, CD4+ T cell counts in blood, and viral 
RNA levels in tissues were determined for all macaques in the study (Error! Reference 
source not found.). To assess the extent of CNS inflammation and pathology, brain 
tissue was evaluated as previously described and scored ranging from none to severe 
(38). These studies were performed in accordance with federal guidelines and 
institutional policies.  
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Isolation of Myeloid Cells and Lymphocytes from Blood and Tissues 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation on a 1.077g/mL Percoll/Hanks gradient (GE Healthcare, Pittsburgh PA) 
according to manufacturer’s protocol. Bronchoalveolar lavage (BAL) was obtained by 
passing 250 mL of sterile saline (Life Technologies, Grand Island NY) via bronchoscope. 
BAL cells were isolated by passing lavage samples through a 183 µm pore size sterile 
mesh. Spleen and lung cells were mechanically removed from tissues using an 18-gauge 
needle and passed through a 100 µm cell strainer. Brain parenchymal macrophages and 
microglia were isolated as previously described (41). 
Blood, BAL, lung, and spleen macrophages were cultured in RPMI 1640 media 
(Life Technologies) supplemented with 20% heat-inactivated human AB serum (Gemini 
Bio Products, West Sacramento CA), 100 U/mL penicillin-streptomycin (Life 
Technologies), 20 µg/mL gentamycin (Life Technologies), 2mM L-glutamine (Life 
Technologies), 2 mM sodium pyruvate (Sigma), 10 mM HEPES buffer (Life 
Technologies), and 50 ng/mL recombinant human Macrophage Colony Stimulating 
Factor (M-CSF) (R&D, Minneapolis MN). Brain macrophages were cultured in DMEM 
(Life Technologies) supplemented with 5% heat-inactivated bovine serum FBS (Atlanta 
Biologicals), 5% IS Giant Cell Tumor Conditioned Media (Irvine Scientific, Santa Ana 
CA), 100 U/mL penicillin- streptomycin (Life Technologies), 70 µg/mL gentamycin 
(Life Technologies), 2 mM L-glutamine (Life Technologies), 3 mM sodium pyruvate 
(Sigma), and 10 mM HEPES buffer (Life Technologies). 
CD4+ T cells were cultured in RPMI supplemented with 10% heat-inactivated 
bovine serum (Atlanta Biologicals), 100 U/mL penicillin-streptomycin (Life 
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Technologies), 1% T cell growth factor (31), and 100 U/mL IL-2 (Novartis, NY, NY). 
Samples were analyzed fresh, or frozen viably and rapidly thawed in corresponding 
media prior cell isolation.  
 
Macrophage Quantitative Viral Outgrowth Assay (MΦ-QVOA) 
Monocytes and tissue macrophages strongly express the integrin CD11b (42), a 
common myeloid marker (43-46). Myeloid cells were purified based on expression of 
CD11b with a non-human primate CD11b antibody-conjugated Microbead kit (Miltenyi 
Biotec, Auburn CA) according to the manufacturer’s protocol. The purified macrophages 
were cultured in triplicate in a ten-fold limiting dilution in the presence of 10 µM 
zidovudine (Sigma) and 25 nM darunavir (Janssen, Titusville NJ) for 3 days for cell 
attachment or 7 days for differentiation of peripheral blood monocytes. Poly-L-lysine 
coated plates (Sigma) were used and plates were spun down at 2,000 rpm (872xg) for 10 
minutes to increase cell adherence. Cells were washed twice with HBSS (Life 
Technologies) to remove non-adherent CD3+ lymphocytes. Media containing 10 ng/mL 
recombinant human Tumor Necrosis Factor alpha (TNFα) (ProSpec, East Brunswick NJ) 
and 1x10^5 CEMx174 cells/well were added to each well. CEMx174 cells served to 
expand the virus released from infected cells as previously described (47). Media were 
replenished with TNFα after 4 days in co-culture; supernatants and cell lysates were 
collected following 12 days of co-culture with CEMx174 cells. The presence of 
replication-competent virus was determined by isolating RNA from supernatant and 
measuring SIV RNA by qRT-PCR. The frequency of cells harboring replication-
competent virus was determined by limiting dilution assay statistics (32) and expressed as 
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infectious units per million (IUPM). Two sets of negative control wells with CEMx174 
cells only were added to the cultures. In addition, to determine the number of CD3+ T 
cells that were in the assay, duplicate control wells of CD11b+ macrophages without 
CEMx174 cells were used to measure TCRβ RNA as described below.  
 
 Generation of RNA Standards for TCRβ  RNA Assay 
RNA isolated from macaque CD3+ T cells was reverse transcribed into cDNA 
using the SuperScript II enzyme kit (Life Technologies) with 4.1mM MgCl2, 0.5 mM 
dNTP, 1mM DTT, 150 ng random hexamers, 1x first strand buffer, and 1 unit of RNase 
OUT in a 20 uL reaction. The sample was incubated at 25oC for 15 min, 42oC for 40 min, 
85oC for 10 min, and 25oC for 10 min. Resulting cDNA was amplified by PCR using the 
PCR SuperMix High Fidelity kit (Life Technologies) with the TCRβ primers as follows: 
Fwd- 5’-GAG GAC CTG AAA AAG GTG TTC-3’, and Rev- 5’-CAT AGA GGA TGG TGG 
CAG ACA-3’, designed for the constant region of TCRβ chain of macaques as previously 
described (48). The mix was incubated for 30 seconds at 94oC followed by 35 cycles of 
94oC for 15 seconds, 50oC for 15 seconds, and 68oC for 30 seconds, then incubated at 
72oC for 10 min. The resulting TCRβ PCR product was cloned into a pCR2.1 TOPO 
vector, sequenced, and confirmed. For in vitro RNA transcription, the plasmid was 
digested with BamHI, and TCRβ RNA was then generated with the Mega Script T7 kit 
(Life Technologies) and used as control transcript for the standard curve.  
 
Quantitation of TCRβ  RNA 
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TCRβ RNA was quantitated by qRT-PCR using QuantiTect Kit (Qiagen), the 
above described primers, and the following probe 5’-/56-FAM/ACT TCC GCT/ZEN/ GCC 
AAG TCC AGT TCT AT/3IABkFQ/-3’ based on sequence analyses of macaque TCRβ 
RNA. Cycling conditions were as follows: 50oC for 30 min, 95oC for 15 min, 45 cycles 
of 94oC for 15 sec, 55oC for 15 sec, and 60oC for 30 sec. 18s ribosomal RNA was 
multiplexed with the TCRβ RNA to control for cell counts. To determine the average 
number of TCRβ copies per CD3+ T cell, PBMCs from seven uninfected macaques were 
labeled with PE-conjugated anti-CD3 clone SP34 (BD Bioscience, San Jose CA) and 
magnetically separated using an EasySepTM PE Positive Selection Kit (Stemcell 
Technologies, Vancouver BC, Canada). Purity of the cells was confirmed by flow 
cytometry (Figure 2A). A minimum of 4 aliquots of a million CD3+ T cells from each 
macaque were used to isolate RNA that was analyzed by qRT-PCR for TCRβ RNA and 




All CD11b+ myeloid cells were labeled with PE conjugated anti-CD3 clone SP34 
(BD Bioscience) and FITC conjugated anti-CD11b clone Bear1 (Beckman Coulter, Brea 
CA) to assess selection efficiency. Purified CD4+ T cells were stained with antibodies for 
HLA-DR clone L243 (Biolegend), CD3 clone SP34-2 (BD Bioscience), CD4 clone 
OKT4 (Biolegend), CD8 clone RPA-T8 (Biolegend), and TCRγδ clone B1.1 
(eBioscience). Cells were stained for 20 minutes at room temperature in 100 µL PBS 2% 
FBS and fixed for 10 min with Fix/Lyse buffer (Becton Dickinson, Franklin Lakes, NJ). 
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After fixation, samples were analyzed in a BD LSRFortessa Flow Cytometer using DIVA 
software (Becton Dickinson, Franklin Lakes NJ). The gating of CD3+ T cells was easily 
visualized as small CD3+ non auto-fluorescent cells. All data were analyzed using FlowJo 




Co-cultured live monocyte-derived macrophages were treated at 37oC for 4 hours 
with 10 µM pHrodo Green Escherichia coli bioparticles (Life Technologies), which can 
be phagocytosed only by functional macrophages and are non-fluorescent at neutral pH, 
fluorescing in the acidic pH of phagosomes (49). Cells were then stained at room 
temperature for 20 minutes with two drops/mL NucBlue Live nuclear marker (Life 
Technologies), a Hoechst 33342 nuclear marker that emits fluorescence when bound to 
DNA (50). Images were taken on a Nikon Eclipse TE200 Fluorescence Microscope and 
merged using Adobe Photoshop CS4 (Adobe, San Jose CA).  
 
T Cell Viral Outgrowth Assay 
Total CD4+ T cells were enriched with a non-human primate microbead isolation 
kit (Miltenyi Biotec), which depleted cells expressing CD8, CD11b, CD16, CD20, CD56, 
and CD66abce. Infected CD4+ T cells were quantified by using a previously described 
five-fold limiting dilution assay (34, 35, 47). Cells were co-cultured with CEMx174 for 
two weeks. Culture supernatant was analyzed for SIV RNA by qRT-PCR. The 
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frequencies of infected cells were determined by limiting dilution assay statistics (32) and 
were expressed in terms of infectious units per million (IUPM).  
 
RNA Isolation from Cells and Tissues 
RNA from cell cultures was isolated with RNeasy Plus Mini Kit (Qiagen, 
Valencia CA) according to manufacturer’s protocol with modifications. An on-column 
DNase digestion was performed using the RNase-free DNase kit (Qiagen) with the 
addition of four units of TURBO DNase (Life Technologies) to the enzyme mix. 200 µL 
of fluid (from CSF, plasma, and culture supernatants) was isolated using the QIAamp 
MinElute Virus Spin Kit (Qiagen) according to manufacturer’s protocol with 
modifications. An on-column DNase digestion was performed using the RNase-free 
DNase kit (Qiagen), with the addition of three units of RQ1 DNase (Promega, Madison 
WI) to the enzyme mix.  
Frozen tissues were isolated with RNase STAT-60 (Tel Test Inc., Friendswood 
TX) and homogenized with the FastPrep®-24 instrument (MP Biomedicals, Santa Ana 
CA) in lysing matrix D tubes (MP Biomedicals). The sample was separated with 
chloroform and the aqueous phase was treated with isopropanol to precipitate RNA. The 
RNA was purified with the RNeasy Mini Kit (Qiagen), with an on-column DNase 
digestion using the RNase-free DNase kit (Qiagen), and the addition of three units of 
RQ1 DNase (Promega) to the enzyme mix. 
 
Quantitation of SIV RNA 
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SIV RNA was measured by qRT-PCR using the QuantiTect Virus Kit (Qiagen) 
and primers in the SIV gag region as previously described (34, 51, 52). Three reactions 
were performed for each sample. To control for DNA contamination, one reaction was 
analyzed without reverse transcriptase. Samples were analyzed using the Rotogene 
thermocycler (Qiagen).  
 
PBMC infection  
PBMCs from uninfected pigtailed macaques were isolated by Percoll density 
gradient and plated in 48 well plates in RPMI media supplemented with 2 µg/mL 
recombinant human IL-2 (Life Technologies) and 2 µg/mL PHA-M (Life Technologies) 
overnight. PBMCs were spinoculated for 2 hours with 100 µL supernatants of triplicate 
independent wells from macaques Pm6 and Pm4 (blood, spleen, microglia and lung) 
MΦ-QVOAs. PBMCs were infected for 5 hours at 37°C, the supernatant was removed, 
and excess virus washed five times with sterile saline. Media were replaced and 
supplemented with 2 µg/mL IL-2 (Life Technologies). Supernatants were collected at 
days 5, 10, and 13 post-inoculation.  
 
SIV env sequence analyses 
Supernatant RNA was reverse transcribed into cDNA using the SuperScript III 
reverse transcriptase enzyme kit (Life Technologies) according to manufacturer’s 
protocol. Resulting cDNA was amplified using the Platinum PCR SuperMix High 
Fidelity kit (Life Technologies), according to manufacturer’s protocol, with two rounds 
of nested PCR against SIV env primers. The primer sequences were as follows: 1st round 
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(Fwd: 5’-ARG AAT GCG ACA ATT CCC CT-3’; Rev: 5’-TCC ATC ATY CTT GTG CAT 
GAA G-3’) and 2nd round (Fwd: 5’- CAG TCA CAG AAC AGG CAA TAG A-3’; Rev: 5’-
TAA GCA AAG CAT AAC CTG GMG GT-3’). Both rounds were amplified with the same 
cycling conditions: 94°C for 1 minute then 40 cycles of 94°C for 30 seconds, 55°C for 30 
seconds, 72°C for 1 minute. Resulting product was ~560 base pairs. The PCR product 
was purified using the DNA clean & concentrator-5 kit (Zymo Research) according to 
manufacturer’s protocol and sequenced on an Illumina MiSeq. Sequences were analyzed 
using Geneious version 8.0 (Biomatters, Auckland, New Zealand).  
 
Statistics 
Infected cell frequencies in limiting dilution assays were calculated using the 
IUPMStats v1.0 infection frequency calculator (http://silicianolab.johnshopkins.edu) 
(32). Correlations were computed using a two-tailed nonparametric Spearman rank 
correlation analysis. Statistics were performed using Prism Software (GraphPad 
Software, La Jolla CA).
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RESULTS  
Development of the macrophage viral outgrowth assay (MΦ-QVOA).  
The viral outgrowth assay used to measure productively infected HIV and SIV 
infected resting CD4+ T cells uses highly purified resting CD4+ T cells that are serially 
diluted and activated with IL-2 (31, 33). To amplify infectious virus produced by CD4+ T 
cells, susceptible human cell lines are added to each well (MT4 or CEMx174 cells) and 
virus in the cell supernatants is quantified by qRT-PCR or ELISA (33-35, 47). The 
frequency of productively infected cells is calculated based on the number of virus or 
viral RNA positive in each of the serial dilutions (32, 33).  
Our macrophage quantitative viral outgrowth assay (MΦ-QVOA) was based on 
same experimental approach as the CD4+ T cell QVOA. Monocytes and tissue 
macrophages strongly express the integrin CD11b (42) and could be separated from other 
cell types by sorting with CD11b Miltenyi magnetic beads (43-46). The CD11b+ cells 
were serially diluted and antiretroviral drugs were added to the culture to prevent virus 
spread from non-adherent CD4+ T cells. Unlike T cells, macrophages do not divide 
exponentially when activated in culture and require adherence to culture plates when 
grown in vitro (53). After monocytes or macrophages adhered to the culture plate, 
residual non-adherent T cells were removed from each well (Figure 1C).  
The purity of myeloid cells selected with CD11b beads was assessed by flow 
cytometry by examining cells that expressed CD3 and CD11b. CD11b+ myeloid cells 
from blood, BAL, lungs, spleen, and brain from fourteen SIV-infected macaques were 
analyzed. Flow cytometry analyses of PBMCs isolated from blood after CD11b+ 
selection showed that there were <1% CD3+ cells in the selected cells (Figure 1A). The 
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percentage of CD11b+ cells selected from tissues ranged from 94% - 99.1% (Figure 1B). 
CD11b+ cells adhered to the culture plates and any residual CD3+ lymphocytes that 
remained in the culture supernatant did not proliferate (Figure 2C).  
To evaluate the presence of contaminating CD4+ T cells in the macrophage 
cultures, CD11b+ macrophage control wells without CEMx174 cells were analyzed at 12 
days post-seeding, lysed, and TCRβ RNA was quantitated by qRT-PCR. TCRβ RNA is 
present in macaque CD3+ T cells with an average of 3.8 ± 0.8 copies per cell, as it was 
determined by qRT-PCR (Figure 2B). 
The number of CD3+ T cells quantified prior to CD11b+ selection, after CD11b+ 
selection, and at the end of the MΦ-QVOAs in the control wells without CEMx174 cells 
was calculated (Figure 2C). On average, less than 0.9% CD3+ T cells remained in the 
monocyte-derived macrophages, 0.3% and 1.5% in the BAL and lung macrophages, 
respectively, 2.5% in the splenic macrophages, and 0.06% in the brain MΦ-QVOAs at 
the end of the assay. Based on the frequency of infection of CD4+ T cells quantitated by 
the standard QVOA in Table 3 and the CD4+ T cell percentages by flow cytometry in the 
blood and spleen, we calculated that there was on average less than one infected CD4+ T 
cell in any of the MΦ-QVOA assays (Table 2). Therefore, the small number of CD4+ T 
cells that remained in the wells was not sufficient to contribute to virus quantitated in the 
MΦ-QVOAs.  
To ensure that SIV virus gene expression was active in all the infected 
macrophages, TNFα, a potent activator of macrophages and the U1 monocytic cell line 
(54, 55), was added to all wells along with CEMx174 cells to expand replication-
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competent viruses. CEMx174 is a T/B cell hybrid line used widely to propagate all 
strains of SIV, including those used to infect the macaques in this study (47, 56).  
Cell supernatants and lysates were isolated separately after 12 days of co-
cultivation (Figure 3A). Viral RNA was isolated from cell supernatants from triplicate 
wells and quantitated individually by qRT-PCR. Wells were considered positive for SIV 
when RNA levels were higher than 50 copies per 200 µL of supernatant, which is the 
threshold of detection for qRT-PCR. The frequency of infectious virus per million 
(IUPM) was calculated using limiting dilution statistical analyses (32).  
To determine the viability of the macrophages co-cultured with CEMx174 cells, 
phagocytosis, a function of viable macrophages, was measured by assessing the number 
of cells that engulfed pHrodo green E. coli bioparticles (Figure 3B). Both CEMx174 cells 
and macrophages were stained with NucBlue live nuclear stain. The number of cells 
stained with both markers in each dilution of macrophages reflected the number of viable 
CD11b+ macrophages plated in the well. Despite the numerous CEMx174 in the co-
culture system and the prolonged cell activation, the number of double-labeled 
macrophages reflected the number originally plated. Furthermore, wells from 106 
CD11b+ macrophages plated with CEMx174 cells (second column) and without (last 
column) showed equivalent number of double-labeled cells. This suggests that the 
macrophages remained viable throughout the MΦ-QVOA experiment despite the co-
culture conditions. Finally, Figure 3B demonstrated that macrophages, unlike 
lymphocytes, did not expand in culture; therefore the MΦ-QVOA assay is only a 
minimum estimate of the size of the reservoir.  
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Quantitation of productively infected myeloid cells and CD4+ T in blood and tissues.  
The SIV MΦ-QVOA assay was used to quantitate the number of productively 
infected monocytes in blood and macrophages in BAL, lungs, spleen, and brain of SIV-
infected macaques (Figure 4). The quantitation of infected macrophages is an estimate of 
infection based on the assumption that the cells isolated are representative of the 
population in each tissue. The frequency of productively infected macrophages in each 
tissue varied among the macaques, with the highest number in spleen (median 424 
IUPM), a secondary lymphoid tissue that contains both CD4+ T cells and tissue resident 
macrophages. The high frequency of productively infected macrophages was found in 
macaques with late stage disease (>84 d.p.i) as well as chronic disease (34-36 d.p.i) 
suggesting that there is a steady state level of infected macrophages in spleen or that there 
is replenishment of infected macrophages throughout infection due to macrophage 
turnover. In lung, the number of productively infected interstitial macrophages were also 
very similar between the animals with late stage and chronic infection and the mean is 
~2.5 fold higher than the infected alveolar macrophages. However, when the interstitial 
and alveolar macrophages were compared within the same macaques, the levels 
correlated significantly (r=1, p<0.05) (Figure 5). The interstitial macrophages are derived 
from blood monocytes, and interestingly, monocyte-derived macrophages from blood had 
31.5 IUPM, equivalent to levels in interstitial macrophages (32.2 IUPM) (Figure 4).  
The majority of the CD11b+ cells isolated from brain represent microglia; 
however, perivascular macrophages, which are monocyte-derived-macrophages from 
blood, also express CD11b. Brain microglia/macrophages had the widest range of 
productively infected cells among all the tissues and between macaques. While spleen 
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contained the highest number of infected cells, the brain of animals with mild to severe 
CNS disease contained the next highest level of infected cells (median 231 IUPM). The 
two macaques with the most productively infected cells (Pm3 and Pm4 with 24,000 
IUPM) had severe encephalitis and high levels of viral RNA in brain. The macaques 
without CNS disease had undetectable numbers of infected microglia/macrophages 
(Table 3) and little or no detectable viral RNA in the brain (Pm9 through Pm12) (Table 
1). The number of productively infected microglia/macrophages trended toward a 
correlation with SIV RNA in the two regions of the brain with the highest levels of viral 
RNA, basal ganglia (r=0.71) and parietal cortex (r=0.64) (Figure 5).  
Productively infected CD4+ T cells in the blood had a median of 206 IUPM, 
almost 10 fold higher than the number of infected monocytes in blood (34, 35). However, 
there was no correlation between plasma viral load and the frequency of infected 
macrophages or lymphocytes in a particular tissue or blood. The QVOAs provided a 
comparison of the minimum estimate of productive infection in the two major SIV target 
cells. Further, it suggested that macrophages are a significant source of virus from tissues 
during chronic infection. 
 
Infectivity and sequence analyses of virus from MΦ-QVOA 
 To confirm that virus produced in the MΦ-QVOAs was replication competent, 
supernatants that contained virus from the MΦ-QVOA from blood monocyte-derived 
macrophages, lung, spleen, and brain of SIV-infected macaques Pm4 and Pm6 were used 
to infect PBMCs isolated from uninfected macaques. After infection, supernatants from 
the newly infected PBMCs were analyzed at multiple time points for SIV RNA by qRT-
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PCR. Viral spread was observed in all wells (Figure 6B), indicating that all original MΦ-
QVOA supernatants contained replication competent virus. Interestingly, wells with <50 
copies per 200 µL of supernatant in the spleen (red symbols) efficiently infected the 
PBMCs suggesting that the virus in the MΦ-QVOAs was infectious even when there was 
low levels of SIV RNA found in the supernatants. This provides evidence that this novel 
viral outgrowth assay functioned like the CD4+ T cell QVOA.  
Sequence analysis of the V1 region of SIV env was performed with virus isolated 
from the QVOA wells done in both CD4+ T cells and macrophages from the spleens of 
SIV-infected macaques Pm4, Pm5 and Pm6. The predominant virus found in the MΦ-
QVOA and the CD4+ T cell QVOA was very similar within the spleens of the same 
macaque (Figure 7A and 7C). Furthermore, the virus produced from CD4+ T cells and 
macrophages of three animals also had very similar sequences (Figure 7B). To exclude 
the possibility of virus selection from co-culture with CEMx174 cells, virus isolated from 
control CD11b+ macrophage wells without CEMx174 cells was also analyzed. Only one 
macrophage control well had a sequence different than the predominant sequence in the 
other MΦ-QVOA wells. This suggests that co-culture with CEMx174 cells did not 
significantly affect the viruses that replicated and were detected in the MΦ-QVOA. 
Further, the similarity of the infectious virus isolated from CD4+ T cells and macrophages 
in spleen during chronic infection suggest that SIV viruses in spleen at this period are 
dual-tropic infecting both CD4+ T cells and macrophages. 
 36 
DISCUSSION 
 HIV and SIV infection in tissues and in vitro has been widely studied. However, 
the number of macrophages in tissues and monocytes in blood that harbor replication 
competent virus has not been quantitated. In this study, we developed an assay to 
measure the number of blood monocytes and tissue macrophages that contain replication 
competent virus. This assay is based on our previous macaque CD4+ T cell QVOA. The 
assay required an understanding that macrophages require culture conditions for 
adherence and that they do not undergo exponential expansion, as do CD4+ T cells.  The 
in vitro culture of primary tissue macrophages also required different conditions for each 
tissue that we studied, unlike isolation of CD4+ T cells from blood and tissues. In order to 
select macrophages from tissues, expression of the CD11b antigen was used since it is 
uniformly expressed on monocytes and macrophages. In addition, to exclude the 
contribution of CD4+ T cells to this assay we developed an assay for the detection and 
quantitation of TCRβ RNA.  
 Using this MΦ-QVOA, we quantitated the number of macrophages that 
contained replication-competent virus in blood, BAL, lung, spleen and brain of SIV-
infected macaques. We demonstrated that macrophages isolated from the blood and from 
several tissues of SIV-infected macaques harbored replication-competent virus. We also 
showed that the blood-derived and tissue macrophages used in the MΦ-QVOA had 
normal phagocytic function and remained viable throughout the assay despite prolonged 
culture and activation with TNFα. Further, virus produced by the cells in the MΦ-QVOA 
was capable of de novo infection of macaque PBMCs. Finally, we characterized the virus 
isolated from the MΦ-QVOA by analyzing env sequences and virus infectivity in 
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PBMCs. Env sequences from viruses isolated from CD4+ T cell and macrophage QVOAs 
were not substantially different. All isolated viruses replicated efficiently in PBMC 
suggesting no selection in macrophages for altered virus tropism. 
The number of productively infected macrophages in a given tissue was 
surprisingly similar from macaque to macaque, whereas the number of productively 
infected macrophages varied widely in different tissues from the same SIV-infected 
macaque. The near 10-fold difference in productively infected monocytes compared to 
CD4+ T cells in blood suggests that monocytes are either less susceptible to SIV 
infection, have a higher turnover, or harbor more viral genomes that are not replication 
competent. The highest number of infected macrophages (424 IUPM) was measured in 
spleen demonstrating that splenic macrophages are highly susceptible to SIV infection 
and harbor high levels of productive genomes. This suggests a role for tissue 
microenvironments in mediating virus infection of macrophages (57, 58). Populations of 
macrophages that reside in each tissue may be differentially susceptible to SIV/HIV 
infection based on the cytokine profiles of the organs (59-61).  
It has been recently demonstrated that tissues contain two phenotypically different 
macrophage populations that are derived either from resident, i.e. fetal-derived 
macrophages or monocyte-derived macrophages that enter tissues from the bloodstream 
(62, 63). There are many indications that both types of macrophages harbor persistent 
virus after ART suppression. HIV patients that have completely controlled plasma viral 
load yet have detectable virus in the CSF, some with accompanying CNS symptoms (64, 
65). HIV and SIV infection in brain is predominantly in resident microglia and 
perivascular macrophages (66-68). In addition, lung inflammation is ongoing in some 
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patients suppressed on ART, in part, due to infected tissue macrophages (69, 70). ART 
suppression of virus replication at all stages of disease likely leads to the persistence of 
infected myeloid cells in tissues. The MΦ-QVOA assay that we have developed can be 
used for human monocytes and macrophages and the TCRβ RNA qRT-PCR assay can 
detect transcripts from both human and macaque CD3+ T cells. The MΦ-QVOA assay 
will be important in measuring the number of myeloid cells in tissues of ART-suppressed 
macaques and HIV-infected individuals on ART. 
We have previously reported a significant correlation between CNS pathology 
and elevated CSF viral load, but not plasma viral load (38); this has also been reported in 
HIV-infected individuals with CNS encephalitis prior to ART (71). Quantitation of 
productively infected macrophages in the brain using the MΦ-QVOA strongly supports 
the hypothesis that CD11b+ microglia/macrophages in the brain are the major 
contributors to CNS infection since the number of infected macrophages in both basal 
ganglia and parietal cortex brain showed a trend towards a correlation with viral RNA 
levels, but not plasma viral load. It is important to note that even in a model with high 
prevalence of CNS pathology similar to human disease, not all of the macaques in this 
study developed severe CNS disease. However, those that did develop mild-severe CNS 
disease had the highest frequency of infected macrophages in the brain. This study 
suggests that the frequency of infection of macrophages in the brain is directly correlated 
with and leads to CNS pathology.  
In this study, both blood and tissue from untreated SIV-infected macaques were 
analyzed because the numbers of productively SIV-infected myeloid cells and CD4+ T 
cells in tissues during infection have not previously been measured. Our results establish 
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that productively infected tissue macrophages can be quantitated, that the virus produced 
is infectious, and that there is no TCRβ RNA detectable in the infected macrophages. A 
recent report concluded that tissue macrophages in SIV-infected macaques contained SIV 
DNA from phagocytosis of CD4+ T cells and that tissue macrophages were not a major 
source of virus in vivo (72). In sharp contrast, we developed novel optimized methods for 
isolation and evaluation of tissue macrophages, to demonstrate clearly that SIV-infected 
tissue macrophages produce abundant replication competent virus. Of note, these novel 
assays provide a minimum estimate of productively infected CD4+ T cells and myeloid 
cells in SIV-infected tissues in vivo. It is possible that phagocytized CD4+ T cells infects 
macrophages in vivo as it has been demonstrated in vitro (73), although a recent study 
using mouse models has indicated that macrophages can sustain replication in vivo 
independently of T cells (74). Using our techniques, it will now be possible to quantify 
the number of latently infected CD4+ T cells and persistently infected myeloid cells that 
harbor replication competent virus in SIV-infected macaques suppressed by ART to 
advance our understanding of HIV latency.  
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Pm 1 62 Severe 166  1,271  6.50E+07 9.85E+06 5.65E+06 4.10E+06  74,024  2.59E+06 
Pm 2 60 Severe 57  45  8.83E+07 2.43E+07 1.30E+06 1.11E+06  99,416   675,000  
Pm 3 50  Severe 113  1,022  4.24E+07 4.98E+06  826,254  1.55E+06  503,785  1.22E+06 
Pm 4 84 Severe 52  4,333  1.49E+09 1.14E+07 4.63E+06 1.92E+06  1,543  1.61E+07 
Pm 5 86 Mild 222 493 1.18E+07 1.84E+07 1.48E+06  807,774   247  1.19E+07 
Pm 6 85 None 396 525 3.65E+08  166,022  699 10,632 1,197 8.45E+06 
Pm 7 83 None 418 767 1.05E+07  117,088  22 14,995 332 8.68E+06 
Pm 8 79  None 56 416 2.20E+06  129,536  ND ND 129 5.51E+06 
Pm 9 87  None 464 874 1.25E+06  112,867  ND ND 152 4.40E+06 
Pm 10 84 None 693  1,071   300,229   12,105   ND  ND  1,797  204,000  
Pm 11a 84 None 119  612   651,191   142,755  196  ND 282  268,000  
Pm 12b 34 None 681 481 4.55E+08  20,761  ND ND 741  866,000  
Pm 13b 35 None 390 350 1.72E+08 8.41E+07 3,365 96,705 421 1.62E+06 
Pm 14b 36 None 758 588 8.37E+07 1.33E+06 1,364 586 253  377,000  
a Treated with fluconazole and paroxetine at day 12 post inoculation. 
b Pre-treated with minocycline 28 days prior infection.  
Treatments did not affect virus replication or progression of disease. 
 
Abbreviations: 
ND: under the limit of detection  
Pm: Pigtail macaque 
��������
48











 T cells of 
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% CD4+ 
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Pm 4  8.08   0.17  48   0.08   0.0   369.97  
Pm 5  40.52   1.27  44   0.56   0.2   139. 38 
Pm 6  205.84   2.01  32   0.64   1.3   23,116.35  
Pm 7  71.06   0   34   0   0  2.07 
Pm 8  1,121.51   0  34   0  0 <0.1 
Pm 9  81.70   2.20  31   0.69   0.6   45.96  
Pm 12 420  0  64   0     0    8.48 
Pm 13 205.84  1.58  32   0.50   1.0   16.97  




 Pm 4 40.52  0.36  17   0.06   0.0  423.93 
Pm 5 9.14  6.23  23   1.41   0.1  854.58 
Pm 6 40.52  5.74  6   0.32   0.1  93,280.33 

























Pm 1 Severe 231.16 
Pm 2 Severe  93.28  
Pm 3 Severe  23,978.95  
Pm 4 Severe  369.97   1,481.48   1,838.35  423.93  23,116.35   8.08   40.52  
Pm 5 Mild  139. 38  57.79   46.23   854.58   427.29   40.52   9.14  
Pm 6 None  23,116.35   18.38  46.07   93,280.33   42.39   205.84   40.52  
Pm 7 None 2.07  71.06   81.70  
Pm 8 None <0.1  1,121.51   205.84  
Pm 9 None  45.96   1.81   <1.0  23.12   <0.42   81.70   205.84  
Pm 10 None  <2.31  
Pm 11 None <1.05 
Pm 12 None  8.48  <1.0  11.56   57.79  <0.2 420 
Pm 13 None  16.97   8.48   18.38   462.33   231.16  205.84 









Figure 1. Analysis of CD11b+ monocytes and macrophages. 
CD11b+ selected cells were stained with antibodies for CD11b and CD3 to identify 
myeloid cells and lymphocytes. (A) Representative flow cytometry dot plots of (left) the 
cell population after non-human primate bead isolation and (right) the highly purified 
population of CD11b+ monocytes. (B) The frequency of CD11b+ (open bars) and CD3+ 
cells (closed bars) was determined by flow cytometry in the indicated compartment.  
(C) Non-adherent cells from MΦ-QVOA were removed and analyzed by flow cytometry. 
Flow cytometry dot plots are shown for a representative animal. Cells were analyzed by 
FSC and SSC (left), and for macrophage and T cell markers (right). Data presented as 














































































































Figure 2. Establishment of the TCRβ  RNA assay. 
CD3+ Lymphocytes from PBMCs of seven uninfected macaques were purified using an 
anti-CD3 antibody positive selection kit. CD3+ cells were analyzed by flow cytometry. 
(A) Representative SSC/FSC dot plots (left) and CD11b/CD3 (right) are shown. (B) The 
average number of TCRβ RNA copies per CD3+ T cell was determined by qRT-PCR. (C) 
TCRβ RNA in MΦ-QVOA cell lysates from indicated compartments was measured by 
qRT-PCR and the average number of CD3+ T cells per 105 cells was calculated prior to 
selection (open bars), following CD11b isolation (hatched bars), and in CD11b+ 
macrophage control wells (closed bars) from MΦ-QVOA. Data represented as mean with 

































































































































































































Figure 3. Macrophage Quantitative Viral Outgrowth Assay (MΦ-QVOA).  
Monocytes from blood and tissue macrophages from BAL, lung, spleen, and brain were 
collected from SIV infected animals and purified by CD11b bead selection. CD11b+ 
selected macrophages were plated in serial dilution, in triplicate wells. Cells were 
cultured with AZT and DRV. Non-adherent cells and anti-retrovirals were removed prior 
to activation with TNFα and co-culture with CEMx174 cells. (A) Schematic of MΦ-
QVOA assay. (B) Live fluorescence microscopy of CD11b+ monocyte-derived-
macrophages co-cultured with CEMx174 cells stained with (top row, blue) Nucblue® 
Live nuclear marker, (middle row, green) pHrodo® green E.coli and merged (bottom 
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Figure 4. Quantitation of SIV infected monocytes, macrophages, and CD4+ T cells 
in SIV infected macaques. 
Monocytes and macrophages from blood, BAL, lung, spleen, and brain were co-cultured 
in MΦ-QVOA assay. CD4+ T cells from the blood and spleen were isolated and plated in 
a limiting dilution similar to MΦ-QVOA assay. Supernatant SIV RNA was measured by 
qRT-PCR, and the frequency of infectious units per million (IUPM) was calculated using 
limiting dilution statistics based on the number of positive wells and the input number of 
cells. The IUPM for macrophages and T cells for each animal assayed is shown with their 
respective symbols. Horizontal black line represents the median IUPM values (displayed 












































Figure 5. Correlation between the MΦ-QVOA and tissue SIV RNA.  
Correlation between the IUPM from brain MΦ-QVOA and basal ganglia tissue SIV RNA 
(A), parietal cortex tissue SIV RNA (B), and CSF viral load (C). Correlation between the 
IUPM in lung macrophages was analyzed against (D) BAL macrophage IUPM. Each 
animal is illustrated with its corresponding symbol, animals with severe CNS disease in 
red. Significance was determined by Spearman’s rank correlation; p<0.05 was considered 
significant.  































































































































Figure 6. Virus produced in MΦ-QVOA is replication-competent.  
Supernatant from Pm4 (filled symbols) and Pm6 (open symbols) from (A) blood MΦ-
QVOA, (B) lung MΦ-QVOA, (C) spleen MΦ-QVOA, and (D) brain MΦ-QVOA were 
collected and used to infect freshly isolated PBMCs by spinoculation. SIV RNA was 
measured in supernatant by qRT-PCR prior to infection (input virus) and longitudinally 
for 13 d.p.i. SIV RNA levels presented as copies per 200 µL. Red symbols indicate wells 
whose input virus was undetectable.






















































































































































Figure 7. Sequence analyses of virus produced in CD4+ T cell and macrophage 
QVOAs. 
Supernatant from spleen MΦ-QVOA and spleen T cell QVOA from Pm4, Pm5, and Pm6 
were collected. Viral RNA was isolated and a two-round nested PCR for SIV env was 
performed. CD11b+ macrophage wells without CEMx174 from the MΦ-QVOA were 
used as controls. The most frequent (red) and the second most frequent (black) sequences 
are depicted along with the frequency of the viral clone indicated in parentheses. (A) 
Nucleotide alignment trees for each animal and (B) phylogenetic tree of all clones are 
shown. (C) Nucleotide sequence alignments are compared with the consensus sequence, 
with percentages signifying the frequency of the prevailing clones. The scale bar 
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The following section of the dissertation is in preparation for publishing and the 
text is quoted verbatim from the following: 
 
Latently Infected Brain Macrophages in SIV-Infected Macaques treated with 
diverse antiretroviral regimens. Claudia R. Avalos, Suzanne E. Queen, Ming Li, Sarah 
L. Price, Erin N. Shirk, Elizabeth L. Engle, Celina M. Abreu, Ellen R. Forsyth, Brandon 
T. Bullock, Feilim. M. Gabhann, Steven W. Wietgrefe, Ashley T. Haase, Joseph L. 
Mankowski, Janice E. Clements, Lucio Gama. Manuscript in preparation. 
 
 
The scientific and technical contributions of the other authors to this work can be 
found in the acknowledgments section at the end of Chapter III. 
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ABSTRACT 
 An HIV cure requires a better understanding of the cellular and anatomical sites 
harboring virus that contributes to rebound upon treatment interruption. Despite 
antiretroviral therapy (ART), HIV-associated neurocognitive disorders (HAND) are still 
prevalent. Biomarkers for macrophage activation and neuronal damage in CSF of HIV-
infected individuals demonstrate continued effects of HIV in the brain and suggest that 
the CNS may serve as a viral reservoir. To evaluate whether infected cells persist in brain 
despite ART, SIV-infected pigtailed macaques were suppressed with multiple ART 
regimens. Plasma and CSF viral loads, and levels of markers of macrophage activation 
and neuronal damage in CSF were analyzed longitudinally. To assess whether virus 
persisted in brain macrophages in these macaques we utilized the macrophage 
quantitative viral outgrowth assay (MΦ-QVOA) as well as in situ hybridization (ISH) to 
measure the frequency and pattern of viral RNA in brain. Despite different ART 
regimens and length of time of ART suppression, all animals had consistently elevated 
markers of neuronal damage and detectable levels of productively infected macrophages. 
ISH in brain showed SIV RNA positive cells. We also showed that virus produced in the 
MΦ-QVOA was replication competent, demonstrating that latently infected brain 
macrophages are capable of re-establishing productive infection upon treatment 
interruption. This study provides the first confirmation of replication-competent SIV in 
brain macrophages of ART-suppressed macaques and suggests that the highly debated 
question of viral latency in macrophages, at least in brain, has been addressed in SIV-




 Resting CD4+ T cells are currently the only cells that fit the definition of a latent 
reservoir. However, recent evidence suggests that HIV/SIV-infected macrophages persist 
despite ART. Markers of macrophage activation and neuronal damage are observed in the 
CSF of HIV-infected individuals and SIV-infected macaques on successful ART 
regimens, suggesting that the CNS has continued virus infection and latent infection. A 
controversy exists as to whether brain macrophages represent a latent source of 
replication-competent virus capable of re-establishing infection upon treatment 
interruption. In this study we demonstrate the presence of the latent macrophage reservoir 
in the brains of SIV-infected ART-treated macaques and quantitate the reservoir using 
our established outgrowth assay to quantitate macrophages harboring replication-
competent SIV genomes. Our results support the existence of other latent reservoirs in 
addition to resting CD4+ T cells and underscore the importance of macrophages when 




Although the frequency of HIV-associated neurocognitive disorders (HAND) has 
decreased with the onset of antiretroviral therapy, milder forms of neurologic impairment 
are still observed in HIV-infected individuals virally suppressed on ART (1-3). HAND is 
thought to be a result of chronic CNS inflammation in the brain (1, 3-5).  It is unclear 
whether inflammation is caused by incomplete penetrance of ART into the CNS and 
persistent virus replication or whether brain macrophages harbor latent virus that 
reactivates causing sporadic inflammatory responses (6). Indeed, some HIV-infected 
individuals on ART have no detectable virus in the plasma but have measurable levels of 
HIV RNA in the CSF (7, 8). There is a continuing debate on the sources of virus in the 
CSF and the cause of the chronic inflammation in brain that leads to HAND.  
Viral replication and activation of brain macrophages during infection contribute 
to the severity of CNS pathology in HIV-infected patients and SIV models of HAND (9-
12). Brain-resident macrophages, which are the main targets of productive HIV infection 
in brain, include perivascular macrophages and microglia, and viral RNA can be detected 
in these cells by in situ hybridization (ISH) in HIV-infected patients (13, 14). Similarly, 
SIV RNA and DNA in SIV-infected macrophages can be detected throughout infection 
(15-20). Moreover, SIV DNA remains in the brain of infected pigtailed macaques despite 
antiretroviral therapy (21). It is still unclear whether brain-resident macrophages are 
latently infected and contain replication-competent virus. 
 Currently, the best-characterized latent reservoir is resting CD4+ T cells (rCD4) 
(22, 23). Further research is needed to demonstrate that macrophages also fit the 
definition of a latent reservoir. Current strategies towards HIV eradication are aimed at 
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reactivating, immunologically eliminating, or excising integrated virus, thus reducing or 
eliminating the functional latent virus reservoirs (24, 25). However, these strategies, such 
as T cell activating cytokines (26), histone deacetylase inhibitors (27), phorbol esters that 
stimulate protein kinase C activity (28, 29) and RNA guided excision of integrated HIV 
(30), have been developed solely to target rCD4. Little is known about the effect of these 
approaches in latently infected macrophages, or whether macrophages will require a 
different strategy for elimination.  
 Measuring the reduction of the latent reservoirs is key in determining the efficacy 
of any strategy to eradicate HIV. For lymphocytes, the frequency of latently infected 
rCD4 in HIV-infected ART-treated individuals is best measured by the quantitative viral 
outgrowth assay (QVOA) (31, 32). Our laboratory previously showed that a similar 
QVOA used to quantify latently infected rCD4 in SIV-infected ART-treated macaques 
yielded frequencies similar to those observed in HIV-infected patients (33). However, 
macrophages had never been examined in a similar manner. Therefore, we developed an 
analogous assay to measure the frequency of productively infected macrophages in 
parallel to rCD4 using the macrophage quantitative viral outgrowth assay (MΦ-QVOA) 
(34). We demonstrated that monocytes from the blood and macrophages from 
bronchoalveolar lavage fluid, lungs, spleen, and brain of chronic SIV-infected pigtailed 
macaques harbor replication-competent virus and showed that CD4+ T cells did not 
contribute to the values from MΦ-QVOA. In this study we examine whether brain 
macrophages isolated from SIV-infected ART-treated macaques represent a productively 
infected latent reservoir, and therefore another barrier to HIV eradication. 
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MATERIALS AND METHODS 
Animal Studies 
Sixteen juvenile pigtailed macaques (Macaca nemestrina) were inoculated 
intravenously with the SIV/DeltaB670 swarm and the molecular clone SIV/17E-Fr as 
previously described (12, 35, 36). Macaques were treated 12 days post-inoculation (d.p.i.) 
with antiretroviral treatment (33). Three regimens of antiretroviral drugs were chosen; 
macaques in each regimen were separated into corresponding cohorts (Table 1). Cohort A 
was treated with 30 mg/kg for the first two weeks then 10 mg/kg of 9-R-(2-
phosphonomethoxypropyl) adenine (PMPA; Gilead Foster City CA) once daily 
intramuscularly (i.m.) as previously described (33), 480 mg/kg darunavir (DRV; Janssen, 
Titusville NJ) orally twice daily, 10 mg/kg of the integrase inhibitor L000870812 (INTI; 
Merck, Kenilworth NJ) orally twice daily, and 24 mg/kg ritonavir (RTV; AbbVie, North 
Chicago IL) orally twice daily. Cohorts B1 and B2 were treated with 30 mg/kg for the 
first two weeks then 10 mg/kg PMPA i.m. once daily, 270 mg/kg atazanavir (ATV; 
Bristol-Myers Squibb, New York NY) orally twice daily, 10 mg/kg of INTI orally twice 
daily, and 24 mg/kg RTV orally twice daily. Finally cohort C was treated with 480 mg/kg 
DRV orally twice daily, 10 mg/kg of INTI orally twice daily, 24 mg/kg RTV orally twice 
daily, and 25/50 mg/kg abacavir (ABC; ViiV, United Kingdom) orally twice daily. 
PmC2, C3 and C5 were supplemented with 200 mg/kg maraviroc (MVC; ViiV) orally 
twice daily. 
In addition to antiretroviral drugs, cohort A was treated with latency-reversing 
agents (LRA). Pigtails PmA1 was kept as control while PmA2 and PmA3 were treated 
with the PKC activator ingenol B (Amazonia Fitoterapicos, Brazil) from 530-574 d.p.i., 
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and then from 592-603 d.p.i. together with the histone-deaceytase inhibitor vorinostat 
(SAHA; Merck) (Figure 1). In cohort B1, Pm B11 was released from antiretroviral drugs 
2 days prior necropsy, Pm B12 was released 9 days prior to necropsy, Pm B13 was 
released 3 days prior to necropsy, and Pm B14 was released 4 days prior to necropsy 
(Figure 1).  
Blood and cerebrospinal fluid (CSF) samples were collected longitudinally. 
Before euthanasia, macaques were perfused with sterile saline to remove blood and 
circulating virus from tissues, as described elsewhere (33). Viral loads in plasma and 
CSF, CD4+ T cell counts in blood, and tissue RNA and DNA levels in parietal cortex and 
basal ganglia were determined for all macaques in the study (Table 1). These studies 
were performed in accordance with federal guidelines and institutional policies.  
 
Brain Macrophage Quantitative Viral Outgrowth Assay (MΦ-QVOA) 
Brain parenchymal macrophages were isolated and cultured for MΦ-QVOA as 
previously described (37). Briefly, myeloid cells were purified based on expression of 
CD11b with a FITC conjugated anti-CD11b antibody (Beckman Coulter, Brea CA) 
followed by the EasySep FITC Positive Selection Kit (Stemcell Technologies). Purified 
macrophages were cultured in triplicate in a ten-fold limiting dilution in the presence of 
10 µM zidovudine (Sigma), 25 nM darunavir (Janssen) and 5 nM raltegravir (Merck) for 
three days for cell attachment in poly-L-lysine coated plates (Sigma). For cohort C, cells 
were washed twice with HBSS (Life Technologies) to remove non-adherent CD3+ 
lymphocytes. For the seeding of macrophages from cohorts A and B, an extra step to 
remove non-adherent CD3+ lymphocytes was performed by briefly incubating the cells 
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with 0.05% trypsin (Life Technologies). In all cohorts, frequency of CD3+ T cells in the 
MΦ-QVOA wells, quantitated by levels of TCRβ RNA, was lower than 3.8 % (Figure 
3B). Brain macrophages were cultured in DMEM (Life Technologies) supplemented with 
5% heat-inactivated bovine serum FBS (Atlanta Biologicals), 5% IS Giant Cell Tumor 
Conditioned Media (Irvine Scientific, Santa Ana CA), 100 U/mL penicillin- streptomycin 
(Life Technologies), 70 µg/mL gentamycin (Life Technologies), 2 mM L-glutamine (Life 
Technologies), 3 mM sodium pyruvate (Sigma), and 10 mM HEPES buffer (Life 
Technologies). Media containing 10 ng/mL of recombinant human Tumor Necrosis 
Factor alpha (TNFα; ProSpec, East Brunswick NJ) was used to reactivate latently 
infected macrophages. In addition to TNFα, 1x105 CEMx174 cells/well were added to 
each dilution. Supernatants were collected and media were replenished with TNFα after 5 
days in co-culture. Supernatants and cell lysates were collected following 10 days of co-
culture with CEMx174 cells. The presence of replication-competent virus was 
determined by isolating RNA from supernatant and measuring SIV RNA by qRT-PCR or 
by measuring SIV p27 in the supernatant. The frequency of cells harboring replication-
competent virus was determined using the IUPMStats v1.0 infection frequency calculator 
(38) and expressed as infectious units per million (IUPM).  
 
Quantitation of CD3+ T cells in MΦ-QVOA wells by the assessment of TCRβ  RNA 
TCRβ RNA was quantitated by qRT-PCR using QuantiTect Kit (Qiagen, 
Valencia CA), as previously described (34). 18s ribosomal RNA was multiplexed with 
the TCRβ RNA to control for cell counts. Duplicate control wells of macrophages 
 71 
without CEMx174 cells were analyzed by qRT-PCR for TCRβ RNA and the number of 
CD3+ T cells was calculated (Table 2).  
 
RNA and DNA Isolation from Cells and Tissues 
RNA and DNA from cell cultures were isolated with Allprep DNA/RNA Mini Kit 
(Qiagen, Valencia CA) according to manufacturer’s protocol with modifications. An on-
column DNase digestion was performed on the RNA isolation column using the RNase-
free DNase kit (Qiagen) with the addition of four units of TURBO DNase (Life 
Technologies) to the enzyme mix.  
SIV RNA from plasma, CSF, plasma, and culture supernatants was isolated using 
the QIAamp MinElute Virus Spin kit (Qiagen) for 200 µL or the QIAamp MinElute 
Virus Vacuum kit (Qiagen) for 1 mL of sample, according to manufacturer’s protocol 
with modifications. An on-column DNase digestion was performed using the RNase-free 
DNase kit (Qiagen), with the addition of three units of RQ1 DNase (Promega, Madison 
WI) to the enzyme mix.  
RNA from frozen tissues was isolated with RNase STAT-60 (Tel Test Inc., 
Friendswood TX). Tissues were homogenized with the FastPrep®-24 instrument (MP 
Biomedicals, Santa Ana CA) in lysing matrix D tubes (MP Biomedicals). After the 
addition of chloroform, samples were centrifuged and the aqueous phase was transferred 
to another tube for RNA precipitation with isopropanol. RNA was purified with the 
RNeasy Mini Kit (Qiagen), with an on-column DNase digestion using the RNase-free 
DNase kit (Qiagen), and the addition of three units of RQ1 DNase (Promega) to the 
enzyme mix. 
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DNA from frozen tissues was isolated with the DNeasy Blood and Tissue Kit 
(Qiagen) according to the manufacturer’s protocol with modifications. Tissues were 
homogenized with the FastPrep®-24 instrument (MP Biomedicals) in lysing matrix A 
tubes (MP Biomedicals). Samples were incubated with 100 mg/mL RNAse A prior to 
DNeasy isolation. 
 
Quantitation of SIV RNA and DNA 
SIV RNA was measured by qRT-PCR using the QuantiTect Virus Kit (Qiagen) 
and primers for SIV gag as previously described (39-41). Three reactions were performed 
for each sample. To control for DNA contamination, one reaction was analyzed without 
reverse transcriptase.  
SIV DNA was measured by qRT-PCR using the MP Kit (Qiagen) and primers for 
SIV gag as previously described. Two reactions were performed for each sample and 
multiplexed with primers for the quantitation of IFNβ. The number of cells per reaction 
was calculated by IFNβ DNA (two copies per cell) and used to normalize cellular SIV 
DNA and RNA from the same isolate. Samples were analyzed using the Rotogene 
thermocycler (Qiagen). 
 
Quantitation of soluble proteins by ELISA 
Levels of CCL2 (R&D Systems, Minneapolis MN), neopterin (IBL International, 
Germany), neurofilament light chain, NF-L (IBL), and IL-6 (R&D Systems) were 
measured longitudinally in the CSF according to manufacturer protocols. SIV p27 
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antigen (Zeptometrix, Buffalo NY) was measured from supernatants of MΦ-QVOA 
according to manufacturer protocol.  
 
In situ hybridization (ISH) 
Eight-micrometer-thick sections from fresh frozen brain (occipital cortex) were 
OCT-embedded and cryosectioned, postfixed in 4% paraformaldehyde, and dehydrated 
through graded ethanols. Tissue sections were rehydrated through graded ethanols, 
treated with HCl, triethanolamine, digitonin, and 4 μg/mL Proteinase K After 
acetylation with acetic anhydride and dehydration, samples were hybridized at 45°C 
overnight with a 35S-labeled riboprobe and 0.5 mM aurintricarboxylic acid in 
hybridization mix. The riboprobe was synthesized from eight approximately 1 kb 
templates using PCR primer sets with SP6 promoters, amplified from B670 cDNA. After 
extensive washes and ribonuclease treatment, tissue sections were dehydrated, coated in 
Kodak NTB emulsion, exposed at 4°C for 7–14 days, and developed and fixed per 
manufacturer’s instructions. They were stained with hematoxylin, dehydrated, and 
mounted with Permount. Photographic images were taken with a digital camera, and the 
section areas were obtained by scanning slides with an Aperio CS2 scanner (Leica) (42). 
 
Cleaved Caspase-3 Immunohistochemistry 
Cleaved caspase-3 was analyzed as previously described (43) using the Leica 
Bond RX automated immunostainer (Leica Microsystems, Germany). Cleaved caspase-3 
antibody (0.252 µg/mL, Cell Signaling, Danvers MA) was used and 
immunohistochemistry performed using the Leica Bond Polymer Refine Detection Kit 
 74 
according to manufacturer’s protocol. The Leica Bond Polymer Refine Red Detection Kit 
was used for double staining with cleaved caspase-3 (0.126 µg/mL, Cell Signaling) and 
CD68 antibodies according to manufacturer’s protocol.  
 
 In vitro infection of peripheral blood mononuclear cells (PBMC)  
PBMCs from uninfected pigtailed macaques were isolated by Percoll density 
gradient and plated in 48 well plates in RPMI media supplemented with 2 µg/mL 
recombinant human IL-2 (Life Technologies) and 2 µg/mL PHA-M (Life Technologies) 
overnight as previously described (34). PBMCs were spinoculated for 2 hours with 100 
µL supernatants of SIV RNA positive wells from brain MΦ-QVOAs. PBMCs were 
infected for 5 hours at 37°C and excess virus was removed after five washes with sterile 
saline. Media were replaced and supplemented with 2 µg/mL IL-2 (Life Technologies). 
Supernatants were collected at days 5, 10, and 13 post-spinoculation.  
 
Statistics 
Infected cell frequencies in limiting dilution assays were calculated using the IUPMStats 
v1.0 infection frequency calculator (http://silicianolab.johnshopkins.edu) (38). Statistics 
were performed using Prism Software (GraphPad Software, La Jolla CA). The Mann-
Whitney analysis of variance test was performed to determine the significant changes of 
infectious units per million (IUPM) in the brain of SIV-infected ART-treated macaques 
compared to SIV-infected untreated animals (p<0.05). Linear regression was used to 
determine correlations between brain IUPM values with corresponding animal 
characteristics (p<0.05).  
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RESULTS 
Variations of viral decay and set point in SIV-infected macaques treated with 
different ART regimens.  
 We have previously demonstrated that daily administration of PMPA, ATV, 
SQV, and INTI suppresses plasma and CSF viremia in pigtailed macaques inoculated 
with SIV/DeltaB670 and SIV/17E-Fr (33). We observed biphasic viral decay in both 
plasma and CSF similar to the decay of HIV in ART-treated individuals. The frequency 
of latently SIV-infected rCD4 in blood was very similar to the frequency observed in 
HIV-1-infected patients on long-term ART (ranging from 0.03 to 3 latently infected 
cells/per million rCD4) (23, 33, 44). To compare the efficacy of different ART regimens 
in suppressing viral replication in the CNS, drug combinations were designed based on 
the CNS penetration-effectiveness (CPE) developed by Dr. Scott Letendre (45). In group 
A (Figure 1A-B, Table 1), to maintain the same CPE rank of 6 used in our previous 
studies, the protease inhibitors (PI) ATV and SQV were substituted by DRV plus the PI 
booster RTV (21, 33). In this group, all treated macaques maintained suppression in 
plasma and CSF for more than 500 days, indicating that successful SIV control could be 
achieved with different PIs as part of the regimen. Two of these macaques (Table 1) were 
also treated with LRAs to test the “shock and kill” strategy for HIV eradication while the 
third animal (PmA1) served as control (manuscript under review, AIDS). Interestingly, 
after the second round of LRA, one of the LRA-treated macaques (PmA3) showed viral 
rebound in plasma and CSF without ART interruption (Figure 1A-B). No viral 
reactivation was observed in the second LRA-treated macaque (PmA2) or the control 
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animal PmA1, indicating that these two macaques emulate the virological control of 
HIV-infected patients in long-term ART. 
 In a second group (Table 1 and Figure 1C-F), seven macaques were treated with a 
less CNS-penetrant regimen (CPE rank of 5) where the combination DRV/RTV from 
group A was replaced by ATV/RTV. ART failed to successfully suppress viremia in 
three out of seven animals with lack of viral control being observed in both plasma and 
CSF (Figure 1E-F). For clarity we divided this group in two subgroups: macaques with 
suppression or efficient control of viremia were grouped as group B1 (Figure 1C-D) 
while macaques in which ART suppression did not lead to fewer than 30 SIV RNA 
copies/ml of plasma were placed in group B2 (Figure 1E-F). After 100 days of viral 
control, ART was interrupted in group B1 animals and macaques were euthanized 24 
hours after detection of viral RNA in plasma (> 100 copies/mL) by qRT-PCR (Figure 
1C-D).  
 A third group of animals (group C; Figure 1 G-H) was treated with DRV/RTV, 
INTI, and the non-nucleoside reverse transcriptase inhibitor ABC, which has a higher 
CPE than PMPA (3 versus 1). Although the regimen is ranked highly penetrant (CPE 
rank of 8), SIV RNA in plasma and CSF continued to be detected for more than 100 days 
post-treatment (Figure 1 G-H). Plasma viremia did not decrease even with the addition of 
MVC to the antiretroviral regimen in macaques PmC2, C3, and C5 (Table 1). 
Interestingly, viral RNA levels in all Group C animals were set 3 to 4 logs lower than 
those observed in SIV-infected untreated macaques (12), suggesting that antiretroviral 
resistance is not the main reason for the viral replication kinetics in these animals.  
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Results from these studies offer an opportunity to evaluate the impact of individual ART 
regimens in control of SIV replication in vivo.  
 
CNS inflammation persists despite antiretroviral treatment 
 To evaluate whether ART-associated viral control in the CNS, measured by CSF 
viral load, is also followed by a decrease in inflammation, CSF samples were collected 
longitudinally and assessed for levels of CCL2 (or monocyte chemoattractant protein-1 
[MCP- 1]), IL-6, neopterin, and neurofilament light chain (NF-L)(46). Elevated levels of 
CCL2 and IL-6 in the CSF have been associated with the development of HAND in 
humans and SIV-infected macaques (47-49). Neopterin is produced by activated myeloid 
cells, which closely correlates to brain inflammation in a variety of disorders, including 
HIV and multiple sclerosis (8, 50), and NF-L is a component of neuronal cytoskeleton 
released to the CSF during neurodegeneration and neuroaxonal damage (46). 
 Levels of activation markers in the CSF were consistently elevated during acute 
infection and decreased during ART, despite the regimen. However, after 100 days of 
suppression, CCL2 (Figure 2A-B) and IL-6 (Figure 2C-D) levels returned to pre-infection 
values in all cohorts while higher levels of neopterin (Figure 2G-H) and NF-L (Figure 
2E-F) were observed in some but not all groups during ART treatment. Neopterin in the 
CSF appear to be related to plasma or CSF viremia, as levels in virally suppressed 
animals (groups A and B1) were similar to those before infection. Further, ART-treated 
animals with limited viral suppression presented significantly higher levels of neopterin 
in CSF, including the macaques in group B2, which were treated with the same regimen 
as B1. Conversely, groups B1 and B2 showed lower levels of NF-L in CSF when 
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compared to the other two regimens, indicating that other events besides viral replication 
are implicated in neuronal damage. 
  
Quantitation of productively infected microglia in ART-treated macaques 
 Activation markers in the CSF have been largely associated with macrophages in 
the CNS (46). The two predominant populations of macrophages in brain are microglia 
and perivascular macrophages. Although the ratio between these two subsets varies 
during HIV/SIV infection and other CNS inflammatory changes, the majority of cells are 
resident microglia (51). Both types of cells are innate immune cell and produce type 1 
interferon stimulating genes and cytokines in response to infection (52). In addition, 
macrophages are the major source of virus replication and virus production in brain. To 
determine the number of productively infected myeloid cells in the CNS, brain 
macrophages from the four cohorts of SIV-infected ART treated animals were isolated 
and the frequency of cells that harbor replication-competent virus was determined by the 
macrophage quantitative viral outgrowth assay (MΦ-QVOA) as previously described 
(34). The method of selection for brain macrophages, CD11b+ selection, does not 
differentiate between distinct subtypes of brain macrophages. Since less than 5% of brain 
myeloid cells are perivascular macrophages (51), we will henceforth use the term 
microglia as a representative of all brain macrophages in the assay. 
 Microglial cells that harbor productively infected SIV virus were found in 13 out 
of 16 macaques (81%) with numbers varying from 0.07 to 4.62 IUPM (Figure 3A and 
Table 2). Levels of infected microglia isolated from SIV infected ART-treated macaques 
were significantly lower than those from SIV-infected untreated animals from a previous 
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study (34) (IUPM median of 0.3 vs. 231, p<0.0005), even for animals that failed to fully 
suppress viral replication in plasma (Figure 3C). There was no significant difference in 
the number of infected microglia between the cohorts, regardless of duration of ART 
treatment and level of plasma viremia, suggesting that SIV reservoirs in brain are 
maintained independently from viral replication in the periphery. In addition, microglia 
IUPM values also correlated poorly with levels of blood CD4+ T cells (R= -0.3122, p= 
0.2375) and monocytes (R= -0.3181, p= 0.2284) quantitated at necropsy. 
 Importantly, there was a significant correlation between terminal CSF viral load 
and number of productively infected microglia measured by MΦ-QVOA (R= 0.5289, 
p=0.037), underscoring the pivotal role of microglia as the major target cells for viral 
replication in brain. These data also corroborate previous findings suggesting that 
microglia function as latent reservoirs for SIV, since a negligible number of CD4+ T cells 
are detected after microglia isolation (Table 2). Indeed, based on the frequency of CD4+ 
T cells in the blood and the estimate that one in a million CD4+ T cells is infected in SIV-
infected ART treated macaques (33), we calculated that fewer than one potentially 
infected CD4+ T cell was present in the macrophage cultures (Table 2).   
 
Brain macrophages harbor SIV latent genomes that can be reactivated 
 The mechanisms that establish or maintain a latent state by HIV or SIV in 
macrophages have not been fully elucidated. Nonetheless, our results confirm that 
microglia harbor replication-competent, transcriptionally silenced viral genomes in vivo 
that can be activated in vitro in the MΦ-QVOA. Analyses of total SIV RNA isolated 
from brain (basal ganglia and parietal cortex) show that significant levels of SIV RNA 
 80 
(>10 copies per µg of tissue) are detectable in only 5 out of 16 of the brain sections 
(31%) (Table 1), indicating that most microglia used in the MΦ-QVOAs were not 
transcribing viral RNA prior to in vitro cultures. In addition, brain SIV DNA was not 
observed in 31% of the animals (5 out of 16), despite high plasma viremia (Table 2), 
supporting the compartmentalization of virus replication during suppressive ART in the 
periphery and the CNS.  
 
Detection of SIV RNA expressing cells by ISH in brain  
 ISH in two regions of brain was performed to investigate the frequency and 
pattern of SIV cell-associated RNA (caRNA) in brain regions in cohorts A and B1. In 
addition, ISH complements the MΦ-QVOA results as another quantitative technique in 
vivo. In cohort A, macaques were suppressed for over 500 days and remained on ART 
while treated with LRA, during which macaque PmA3 had reactivation of virus in CSF 
(Figure 1). In contrast, cohort B1 macaques were suppressed for 100 days, released from 
ART, and then euthanized 24 hours after detection of viral RNA in plasma (>100 copies 
/ml) by qRT-PCR. Brain sections (occipital cortex) from macaques PmA1, A2, A3, B13, 
and B14 were analyzed. RNA positive cells were found in the occipital cortex of 
macaque PmA3 (Table 3 and Figure 4) at a density of 2,220 SIV+ cells per gram of tissue 
whereas PmA1 had a ten fold lower density (202 SIV+ cells/gram of tissue) in occipital 
cortex. In both macaques the pattern of in situ positive cells was single positive foci per 
analyzed area, suggesting that expression of SIV RNA in the brain occurred without viral 
spread to other cells. Macaque PmA2 had no detectable SIV RNA+ cells in the areas 
analyzed. In contrast, macaque PmB13 (ART released) presented a higher frequency of 
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SIV RNA+ cells (10,553 SIV+ cells/gram of tissue) arranged in clusters, suggesting virus 
spread (Table 3). In addition, macaque PmB13 had detectable viral RNA in CSF (168 
SIV RNA copies/mL of CSF). Conversely, macaque PmB14 had undetectable SIV RNA 
by ISH in brain and undetectable viral RNA in CSF. Interestingly, macaque PmB14 had 
low but detectable viral RNA in plasma (225 SIV RNA copies/mL,) (Table 1) suggesting 
that early virus rebound in plasma had not spread to the CNS.  
ISH of SIV RNA in brain and the MΦ-QVOA provide very different quantitative 
approaches to detecting productively infected cells. While ISH analyzes multiple thin 
sections from brain regions and quantitates cell expression of SIV RNA, the MΦ-QVOA 
detects replication-competent virus in isolated cells. Our group routinely isolates 
microglial cells from basal ganglia, leaving other brain regions, such as occipital cortex, 
for ISH and immunohistochemistry. MΦ-QVOA from SIV-infected macrophages 
isolated from basal ganglia were positive despite no detectable SIV RNA by HIS was 
observed in the same section (Table 1), suggesting that there are far more cells in the 
brain harboring SIV genomes but not expressing viral RNA. Thus, these complementary 
quantitative techniques strongly support that microglia in the brain of SIV-infected ART 
treated macaques harbor latent genomes and represent a functional viral reservoir.  
 
Low levels of cleaved caspase-3 reveal microglia are a stable reservoir 
 To examine whether the microglial cells in the brain undergo apoptosis during 
ART suppression, immunohistochemistry (IHC) for cleaved caspase-3 (a marker of 
apoptosis) and CD68 (a marker for macrophages) was performed on brain sections from 
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ART-suppressed macaques (Figure 4C). Low levels of cleaved caspase-3 expression 
were found in the both ART-treated and untreated macaques (PmA3, left vs. Pm4, right). 
Even in the SIV-infected animal with encephalitis (Pm4 from a previous study (34)) there 
were very low levels of expression of cleaved caspase-3 and no co-localization with 
CD68. In brain of the ART-treated macaque, cleaved caspase-3 was rarely observed 
indicating limited apoptotic events in brain macrophages (Figure 4C). The lack of 
significant apoptosis in brain or in brain myeloid cells of the ART suppressed macaques 
provided further support for long-term persistence of brain microglia during ART 
suppression.   
 
SIV virions released by brain macrophages are replication competent  
 We observed that, in some MΦ-QVOA wells, the levels of SIV RNA or p27 were 
low, suggesting that the virus was not spreading within the CEMx174 cell line used to 
amplify the virus released by the activated microglia. To evaluate whether the virions 
measured in the MΦ-QVOA represented replication competent virus, supernatants 
collected from microglia MΦ-QVOAs were combined with PMA/IL-2-activated 
uninfected macaque peripheral blood mononuclear cells (PBMCs) and centrifuged for 2 
hours to spinoculate the cells. PBMCs were then incubated for 13 days, supernatants 
collected at days 5, 10 and 13 p.i, and viral RNA was isolated from the combined time-
points. Quantitation of SIV RNA from the MΦ-QVOA supernatants (input virus) and 
from the infected PBMCs (output virus) is shown in Figure 5. Increase in virus particles 
was observed in all samples, indicating that the supernatants from the MΦ-QVOA wells 
contained infectious virus (Figure 5). Moreover, replication-competent SIV was observed 
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in microglia MΦ-QVOAs isolated from long-term suppressed animals (group A), 
corroborating our previous findings that brain macrophages harbor latent virus genomes 




 One of the major concerns during the initial development of combined ART was 
whether the compounds would efficiently cross the blood brain barrier and control viral 
replication in the CNS (53). In the ART era, signs of chronic systemic inflammation are 
observed in a large percentage of treated patients, even when blood viral load is 
undetectable and CD4+ T cell counts are restored to pre-infection levels (54, 55), 
suggesting that viral reservoirs persist in organs and tissues where ART has suboptimal 
penetrance, such as the brain. Indeed, HAND is still prevalent in ART-treated patients 
(56). In addition to the evident symptoms associated with neurological dysfunction, such 
as memory loss and neuropathy, these patients present a 3-fold increased risk of mortality 
when compared to their HIV-infected non-HAND counterparts (57). A study using 
tissues from the National NeuroAIDS Tissue Consortium established an association 
between these morbidities and viral replication in the CNS (58). A broad prevalence of 
HIV DNA and RNA was reported in 148 brain specimens of cART-treated patients, and 
higher levels of viral nucleic acids were detected in patients with neuropathological 
evidence of HIV encephalitis, despite undetectable plasma viral load (58). These findings 
reaffirm the importance of the brain as a potential viral reservoir during ART. 
 In contrast to CD4+ T lymphocytes in the periphery, the majority of HIV-infected 
cells in the CNS are microglia, perivascular macrophages, and astrocytes (59-61). These 
cells present distinct surface markers and transcriptional networks, which explain why 
HIV strains identified in the CNS frequently diverge from the ones found concomitantly 
in the blood of the same patient (62). In addition, at least in CD4+ lymphocytes, HIV 
latency is a multifactorial process in which distinct mechanisms, at times in cooperation, 
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drive the virus into transcriptional silence (63). In brain macrophages, however, specific 
mechanisms for the establishment of viral latency require further examination. For 
instance, IFNß is able to modulate viral transcription in macrophages - but not in 
lymphocytes - by increasing the expression of the truncated, dominant-negative form of 
the transcription factor C/EBP-ß (64, 65), and the repressor CTIP2 is able to inhibit HIV 
transcription by recruiting chromatin-modifying complexes in microglial cells (66).  
 Part of these assessments can be done in vitro using HIV and human cells. 
However, in vivo experiments using SIV strains combined with a consistent macaque 
model allow for a more accurate translational evaluation, providing opportunities to 
characterize viral reservoirs in tissues not easily obtained from HIV-infected patients. 
Using our consistent and accelerated SIV pigtailed macaque model for HIV/AIDS and 
HAND, we have previously established a robust SIV model of ART with the combination 
of four antiretroviral drugs (67, 68). To evaluate the efficacy of other drug combinations 
in control of viral replication in the periphery and CNS, we tested other CNS-penetrant 
antiretroviral combinations that closely reflect regimens used by HIV-infected patients. 
 Despite the suppression of viral replication in the brain in the majority of animals, 
inflammatory markers that reflect macrophage activation (neopterin), neuronal damage 
(neurofilament light chain) were detected in the CSF in SIV-infected macaques from all 
cohorts, including those suppressed for more than 18 months. These results corroborate 
findings in HIV-infected ART-treated patients (69-71) and suggest continued 
inflammation in brain, possibly caused by the presence of suppressed or latent virus in 
the CNS. This hypothesis is supported in this study by the detection of latent, but 
replication-competent, SIV in brain using an MΦ-QVOA developed in our laboratory 
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(34). We had previously demonstrated that the MΦ-QVOA could be used to quantify 
purified populations of macrophages from SIV-infected macaques. In addition, we 
compared the level of productively infected macrophages to CD4+ T cells measured by 
QVOA (34). In this study we demonstrate that the MΦ-QVOA is a sensitive and specific 
assay to measure the number of productively infected cells in brain of SIV-infected 
macaques suppressed with ART. The MΦ-QVOA detected replication competent virus in 
microglia isolated from regions of brain with no detectable SIV RNA providing the first 
demonstration of productively infected latent microglia in brain. In addition, we 
demonstrated that virus isolated from MΦ-QVOA is infectious in primary macaque 
PBMCs, which is additional corroboration for a functional latent reservoir in the brain. 
Further, by sensitive measures of TCRß RNA in the MΦ-QVOA we provide strong 
evidence that there is no contribution of infected CD4+ T cells to our findings.  
 Further, SIV RNA+ macrophages were detected by ISH, not only in the brain of 
macaques Pm A3 and Pm B13 with detectable SIV RNA in the CSF, but also in the brain 
of macaque Pm A1, which was fully suppressed on ART. These results strongly suggest 
that microglia harbor replication competent virus in ART-suppressed macaques in a 
latent form that is reactivated at low levels during suppression (macaque Pm A1 with 202 
SIV+ cells/gram of tissue), which accounts for the continued expression of neopterin and 
NF-L. However, when virus is activated by LRAs (macaque Pm A3) or rebound after 
ART interruption (macaque Pm B13), a higher level of reactivation of the microglial 
latent reservoir (2,220 and 10,553 cells/gram of tissue, respectively) is observed, with 
concomitant increase of the macrophage activation marker neopterin. 
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After 1.7 years of viral suppression in cohort A, macaques PmA1 and PmA2 
showed no viral RNA in basal ganglia and parietal cortex whereas PmA3 had viral RNA 
in occipital cortex (a brain section not used for the MΦ-QVOA). Nevertheless, all three 
macaques in cohort A had replication competent virus produced in the isolated microglia. 
The ISH provided different result than the MΦ-QVOA probably due to the different brain 
regions used for the two assays, occipital cortex used for the in situ hybridization had 
detectable viral RNA and was in situ positive. Furthermore, SIV-infected macaques 
suppressed for six months with little or no detectable virus in the CSF and low levels of 
SIV RNA in brain also had latently infected microglia that produced virus in the MΦ-
QVOA. 
 The demonstration that there is latent replication-competent virus in macaque 
brain provides a mechanism for the ongoing macrophage activation. Recent studies have 
suggested that, while virus does not spread during ART suppression, there is ongoing 
stochastic activation of virus genomes in latently infected cells (72, 73).  Reactivation of 
virus without spread in the macrophage is likely to induce innate immune responses and 
cellular activation. In addition, the extremely low level of apoptosis detected in the brain 
of the suppressed macaques further suggests that the latent microglia reservoir is stable 
and does not undergo significant loss due to cell death. Thus, our demonstration of 
productively infected latent microglia in the brain provides a mechanism for the ongoing 
inflammation of HIV in a fully suppressed individual.  
 The presence of a long-term functional reservoir of SIV in brain that parallels the 
biologic and pathologic features of HIV-infected individuals with HAND presents a 
formidable barrier to strategies to decrease or eliminate the HIV reservoir. First, the brain 
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is protected by the blood brain barrier, therefore special eradication approaches are 
required for successful CNS penetrance. Also, strategies that include activation of virus 
in brain may cause inflammation and neuronal toxicity due to an exacerbated macrophage 
activation and production of cytokines, which are present during latent HIV infection. 
However, if the brain is excluded from eradication strategies, there is the potential for 
incomplete elimination of a functional latent reservoir that can be reactivated when ART 
is stopped, resulting in the spread of reactivated CNS virus to peripheral blood and 
tissues. Our studies suggest that the brain harbors a functional latent SIV reservoir and 
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Table 2. Estimate of the number of SIV+ CD4+ T cells in M!-QVOA wells based on 
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 Pm A1 1.41x108 0,1,0,0,0,0,0 202 
Pm A2 2.54x108 0,0,0,0,0,0,0 <102a 






Pm B13 1.41x108 24,5,23,19,28 10,553 









Figure 1. Viral load measurements of four cohorts of SIV-infected ART treated 
macaques.  
Four cohorts of SIV-infected pigtailed macaques were treated with different ART 
regimens, marked in green. Macaques in cohort A (graphs A and B) were also treated 
with LRAs (orange and purple lines). Macaques in cohort B1 (graphs C and D) were 
released from ART (light blue lines). Macaques in cohorts B2 (graphs E and F) and C 
(graphs G and H) did not suppress viral replication during ART. Median values for each 
group of animals are depicted in red for plasma and dark blue for CSF.  
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Figure 2. Longitudinal measurement of markers of macrophage activation and 
neuronal damage in CSF.   
CSF was analyzed longitudinally for each cohort. Relative concentrations of CCL2 (A-
B), IL-6 (C-D), NF-L (E-F), and neopterin (G-H) are shown. Graphs A, C, D, and E 
represent the median concentration and standard deviation in each group. Scatter plots 
show individual values for each macaque at 100 days post ART. Horizontal black lines 


































































































































































































































Figure 3. Quantitation of latently infected microglia in ART treated macaques by 
MΦ-QVOA. 
(A) Quantitation of infected brain macrophages from four cohorts of ART-treated 
macaques. Number of functionally SIV-infected macrophages for each animal is shown 
with their respective symbols. Horizontal black line represents the median IUPM values 
(displayed on the x-axis). (B) TCRβ RNA levels in MΦ-QVOA cell lysates were 
measured by qRT-PCR and the number of CD3+ T cells per 105 cells was calculated prior 
to CD11b+ isolation or plating (pre-selection) and in macrophage control wells of the four 
cohorts. Data represented as mean with standard error. (C) Numbers of functionally SIV-
infected brain macrophages treated with or without ART are compared. Horizontal black 
line represents the median IUPM values. Significance was determined by Mann-Whitney 














































































































































Figure 4. ISH and IHC analysis from brain sections. 
(A) Representative in situ hybridization from occipital cortex brain sections for SIV 
RNA of PmA3 (top row) and PmB13 (bottom row). (B) Quantitation of SIV+ cells per 
gram of brain tissue by ISH for indicated animals. Symbol (+) represents values below 
the limit of detection. (C) IHC for cleaved caspase-3 (brown) and CD68 (pink) in basal 
ganglia of PmA3 (left) compared to a SIV-infected macaque untreated with ART with 
















































Figure 5. SIV virus produced by microglia in MΦ-QVOAs is infectious. 
 Supernatant from SIV infected microglia MΦ-QVOA wells were collected and used to 
infect freshly isolated PBMCs by spinoculation. (A-C) SIV RNA was measured in 
supernatant by qRT-PCR prior to infection (input virus) and from combined collections 
of 5, 10, 13 d.p.i. PBMCs (output virus). Individual wells used from each cohort are 
individually labeled per corresponding pigtailed macaque. SIV RNA levels presented as 




























































































 IV. Summary of Findings and Future Directions 
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Summary of Findings   
Pigtailed macaques were infected with SIV/DeltaB670, a viral swarm and the 
macrophage-trophic clone, SIV/17E-Fr. Monocytes from blood and macrophages from 
bronchoalveolar lavage fluid, lung, spleen, and brain from fourteen SIV-infected 
macaques were isolated and the frequency of infected macrophages was quantitated using 
a macrophage quantitative viral outgrowth assay (MΦ-QVOA). CD4+ T cells from the 
blood and spleen were isolated and quantitated in parallel using the gold standard, CD4+ 
T cell quantitative viral outgrowth assay (QVOA).  To ensure that only virus produced by 
macrophages were quantified in the MΦ-QVOA, myeloid cells were selected based on 
expression of CD11b and plated in serial dilution in the presence of antiretroviral drugs. 
Macrophages naturally adhere to the tissue culture plates while CD4+ T cells (the other 
SIV infected cell) are non-adherent cells and were removed prior quantification of 
infected macrophages. CD11b+ isolation was successful in discriminating myeloid cells 
with little to no CD3+ T cells remaining in the macrophage culture. However, to ensure 
that there were very few CD4+ T cells we quantified the number of CD3+ T cells 
remaining in the MΦ-QVOA. A TCRβ assay was developed which detected the number 
of TCRβ RNA copies, expressed only in CD3+ T cells, and calculated the number of 
CD3+ T cells in each macrophage isolate. Less than 1 infected CD4+ T cell remained in 
any of the MΦ-QVOA, thus the virus produced in the assays originated from infected 
macrophages not CD4+ T cells. The frequency of infected macrophages in brain and 
spleen of SIV-infected macaques mirrored that of CD4+ T cells in the blood (424 and 231 
vs. 206). The number of infected macrophages in the lung, BAL and blood were more 
analogous to spleen CD4+ T cell infection (31, 13, 32 vs. 61 respectively).  Five of the 
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animals in the study developed CNS pathology, which was scored as mild or severe 
encephalitis. Interestingly, the frequency of infected macrophages in the brain correlated 
with tissue RNA in parietal cortex and basal ganglia, supporting the hypothesis that 
infection of macrophages are the main contributors to CNS infection.  
Following the completion of this study, we hypothesized that infected 
macrophages in brain had the potential to become latent in SIV-infected ART-treated 
pigtailed macaques. Sixteen animals were treated with three ART regimens organized in 
four cohorts. The ART regimens were chosen based on their CNS penetrance score 
(CPE). Cohort A was treated with a highly penetrant regimen (score of 6) and maintained 
suppression for 500 days after which they were treated with latency reversing agents 
(LRAs). The second ART regimen was less penetrant (score of 5), the animals were 
divided into two cohorts based on viral suppression. Animals that maintained suppression 
were released from ART treatment a few days prior sacrifice. The fourth group of ART 
treated macaques did not achieve suppression despite the highly penetrant regimen (score 
of 8), and virus was detected throughout the study, albeit 3 to 4 logs lower than that 
observed in untreated macaques. Despite the differences in ART regimens and duration 
of suppression, latently infected brain macrophages were observed by ISH and MΦ-
QVOA. As previously discussed, TCRβ assay demonstrated that less than 1 infected 
CD4+ T cells remained in the MΦ-QVOA, thus lymphocytes did not contribute to the 
virus produced in the assay. ART treatment was sufficient to significantly decrease the 
frequency of infection of brain macrophages compared to the SIV-infected untreated 
macaque study. Finally, we demonstrated that replication-competent virus was produced 
in the MΦ-QVOAs; by using the MΦ-QVOA supernatant to infect PBMCs. Altogether 
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we demonstrated that brain macrophages are latently infected in ART-treated macaques 
and represent a functional viral reservoir capable of re-seeding the periphery upon 
treatment interruption.  
 
Optimization of MΦ-QVOA 
Devising a macrophage quantitative viral outgrowth assay to measure the number 
of infected macrophages in SIV-infected pigtailed macaques required surpassing multiple 
obstacles. Prior to developing the MΦ-QVOA we needed to isolate a pure population of 
macrophages or deplete all CD3+ T cells in the assay. First, we attempted to remove all 
CD4+ and CD8+ T cells based on expression of CD3 using two strategies: 1) CD3 
antibody-mediated complement killing, and 2) CD3 depletion by magnetic bead isolation. 
The first strategy failed to eliminate the lymphocytes in the cultures (data not shown). For 
the second strategy, we needed to develop our own custom magnetic bead isolation kit 
for CD3 lymphocytes in non-human primate cell preparations. To do so, blood PBMCs 
were isolated and labeled based on expression of CD3 with a PE conjugated anti-CD3 
antibody (clone SP34, BD Biosciences) that cross-reacted with our pigtailed macaque 
samples. Following cell labeling, the EasySep PE Positive Selection Kit (Stemcell 
Technologies) provided us a magnetic bead isolation system that specifically bound all 
PE conjugated cells. Although the CD3 positive selection kit produced 99% pure CD3+ 
lymphocytes in the positive isolation fraction, the depleted fraction contained 7% CD3+ T 
cells and only 20% macrophages (Figure S1). Therefore, we concluded that isolating a 
pure population of macrophages, rather than depleting CD3+ cells, would be a better 
approach.   
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 CD14 and CD11b, two markers consistent among macrophage populations were 
tested. Spleen macrophages from three pigtailed macaques were isolated based on 
expression of CD14 with the non-human primate CD14 microbead kit (Miltenyi) or based 
on expression of CD11b with the non-human primate CD11b microbead kit (Miltenyi). 
Both isolation strategies produced an average of 47% and 67% macrophages respectively 
in the positive fraction with less than 12% and 7% CD3+ T cells remaining respectively 
(Figure S1). However, we suspected that the tissue digestion techniques used on spleen 
preparations disrupted the CD14 surface marker expression because an average of 32% 
macrophages were recovered in the negative fraction of the CD14 kit, whereas only 2% 
were recovered in the negative fraction of the CD11b kit (Figure S1). We concluded that 
the CD11b surface marker was a better surface marker for the purification of tissue 
macrophages and blood monocytes.  
During ART treatment, the frequency of latently infected cells significantly 
decreases to 1 or less than 1 infected cell in a million. Therefore, it became increasingly 
important to not only isolate a pure population of macrophages, but also optimize the 
yield of the isolation technique such that we could assay more than a million cells in 
triplicate. We observed that purification using the CD11b non-human primate microbead 
kit (Miltenyi) yielded variable results. We suspected that using a column-based system 
resulted in loss of myeloid cells during the purification procedure due to macrophages’ 
strong adhesion to the columns. Therefore, we decided to move on to a column-free 
isolation technique using a FITC conjugated anti-CD11b antibody (clone Bear1, 
Beckman Coulter) followed by the EasySep FITC Positive Selection Kit (Stemcell 
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Technologies). The EasySep FITC kit improved our recovery of CD11b+ macrophages 
while maintaining a 90% or greater purity (data not shown).  
 Finally, optimizing the MΦ-QVOA required testing several macrophage 
activation agents. In a small study of five SIV-infected pigtailed macaques, brain 
macrophages were isolated and plated alone, with CEMx174 cells, CEMx174 cells with 
LPS, and CEMx174 cells with PHA. Preliminary data from this study showed that 
macrophages co-cultured with CEMx174 consistently produced SIV+ assays. PHA and 
LPS had little to no effect in activating brain macrophages to produce virus (data not 
shown). Next, we tested the effect of TNFα in activating brain macrophages from two 
SIV-infected pigtailed macaques. In both cultures, TNFα increased the number of SIV 
positive dilutions, thus we concluded that TNFα and CEMx174 co-culture optimized the 
limit of detection of the MΦ-QVOA.  
In other small studies, we tried to re-activate latently infected cells with IL4, LPS, 
IL10, IL1β, prostaglandin E2 (TLR4 agonist), PAM3CSK4 (TLR2/1 agonist), PMA, and 
Ingenol B. However, all of our attempts have been unsuccessful and only TNFα in 
combination with prostaglandin E2 and PAM3CSK4 have shown slightly improved re-
activation in comparison to TNFα alone (data not shown). Furthermore, we observed that 
macrophage escape from latency is highly variable; for example, brain macrophages 
sometimes produce virus early during the MΦ-QVOA assay but later become silenced. 
Additionally, the majority of the MΦ-QVOA cultures are SIV DNA positive but not all 
reactivate to produce SIV RNA despite prolonged TNFα activation or TNFα in 
combination with prostaglandin E2 and PAM3CSK4 (data not shown).  
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Further research is needed to understand the behavior of latently infected 
macrophages and the best strategies of re-activation of latently infected macrophages in 
vitro and in vivo. Understanding the cells that comprise latent reservoirs and their 
frequency of infection compared to CD4+ T cells, the recognized long lived viral 




The research included in this dissertation demonstrated that macrophages are 
infected in the SIV-infected tissues and that virus persists despite ART treatment in the 
brain. However, latency has never been demonstrated in tissue macrophages. We 
hypothesize that SIV-infected tissue macrophages also persist in tissues of ART-treated 
macaques. Thus we performed the MΦ-QVOA in blood monocytes and tissue 
macrophages from BAL, lungs and spleen of the sixteen SIV-infected ART-treated 
macaques previously discussed in section III. Monocytes and macrophages were 
magnetically isolated based on their expression of CD11b and plated in serial dilution. 
TCRβ RNA was quantified (Figure S2) and less than 5% CD3+ T cells remained in the 
spleen, which had the highest number of CD3+ T cells. The number of CD3+ T cells 
remaining did not contribute to the virus observed in the MΦ-QVOA. Next, infection in 
monocytes and macrophages from tissues, and resting CD4+ T cells was quantified 
(Figure S3). The size of the reservoir was consistent between BAL, lung and spleen 
macrophages and CD4+ T cells in the blood (1.2, 1.5, 1.4 vs. 1.3 infected cells per million 
respectively), with spleen macrophages having the widest range of infected cells. The 
 113 
size of the viral reservoir in spleen resting CD4+ T cells was the largest of the tissues 
studied (6.9 IUPM), also varying widely. Finally, similar to our study of brain 
macrophages, ART treatment allowed the establishment of a latent reservoir in all the 
tissues (Figure S4), which was significantly lower than in SIV-infected untreated 
macaques.   
Future directions of this research include characterizing the sequences of the virus 
produced in the MΦ-QVOA and comparing them to the virus obtained from resting CD4+ 
T cells. Additionally, we will investigate whether the virus produced in all tissue MΦ-
QVOAs is functional, and examine whether it is capable of re-seeding the periphery. 
Finally, we will measure the half-life of latently infected cells (macrophages and 
lymphocytes) using mathematical models and study the effect of  “shock and kill” latency 
reactivating agents in reducing the size of the latent reservoirs as a viable cure strategy.  
 
Implications for HIV research 
We showed that the frequency of latently infected macrophages is rare but could 
lead to re-infection upon treatment interruption despite eradication of HIV infection in 
CD4+ T cells. More than ten million purified macrophages are needed to measure the size 
of the latent myeloid reservoir. Translating the results in this study to human experiments 
will require performing multiple biopsies of infected tissues for detection of latently 
infected macrophages. Spleen extractions during surgical procedures in HIV+ patients 
could be used to study latently infected macrophages and re-capitulate the pigtailed 
macaque results.  
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Several questions remain about macrophage infection in HIV. Further research is 
needed to identify which sub-sets of macrophages are latently infected in tissues and 
whether macrophage activation/polarization agents have any effect in promoting latency. 
Moreover, studying the transcriptome and metabolic state of latently infected 
macrophages may allow for better targets of latency reversal. Additionally, it is unclear 
whether latently infected macrophages continue to present HIV peptides, or whether 
cytokine activation because of other infections contributes to bystander HIV infection. 
Finally, more work is needed to determine whether a sterilizing cure that aims to 
eliminate all latently infected macrophages and lymphocytes will ever be possible. A 
functional cure may be more achievable by permanently silencing all latently infected 
macrophages and CD4+ T cells rather than re-activating them.  
We hope that the work presented in this dissertation will change how 
macrophages are perceived in the field of HIV persistence. We have demonstrated that 
macrophages are clearly not a silent player in HIV infection and must be taken into 









Figure S1. Efficiency of magnetic bead isolation strategies used to purify tissue 
macrophages. 
Flow cytometry analysis for CD11b (macrophages) and CD3 (lymphocytes) was 
performed prior to the isolation strategy and in the two resulting fractions. (A) Both 
CD4+ and CD8+ lymphocytes in blood PBMCs were isolated based on expression of CD3 
with a PE conjugated anti-CD3 antibody followed by the EasySep PE Positive Selection 
Kit (Stemcell Technologies). (B) Spleen macrophages were isolated based on expression 
of CD14 with a non-human primate CD14 microbead kit (Miltenyi). (C) Spleen 
macrophages were isolated based on expression of CD11b with a non-human primate 
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Figure S2. Quantitation of CD3+ T cells in MΦ-QVOA by TCRβ  RNA assay 
TCRβ RNA in MΦ-QVOA cell lysates was measured by qRT-PCR and the number of 
CD3+ T cells per 105 cells was calculated prior to CD11b+ isolation (or plating) and in the 
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Figure S3. Quantitation of latently infected cells in tissues of SIV-infected ART-
treated macaques. 
Quantitation of infected macrophages and CD4+ T cells in blood, bronchoalveolar lavage 
fluid, lung, and spleen from the four cohorts of ART-treated macaques. The IUPM for the 
animals assayed is shown with their respective symbols. Horizontal black line represents 




















































Figure S4. ART treatment is sufficient in decreasing the size of the reservoir 
IUPM values from brain macrophages of SIV infected pigtailed macaques treated with or 
without antiretrovirals are compared in blood monocytes (A), spleen macrophages (B), 
lung macrophages (C), BAL macrophages (D), and resting CD4+ T cells in blood (E) and 
spleen (F). Horizontal black line represents the median IUPM values. Significance was 
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